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ABSTRACT
Selective gene expression is crucial in maintaining the self-renewing and
multipotent properties of stem cells. Mediator is a large, evolutionarily conserved, multisubunit protein complex that modulates gene expression by relaying signals from cell
type-specific transcription factors to RNA polymerase II. In humans, this complex
consists of 30 subunits arranged in four modules: head, middle, tail, and kinase. In our
introduction, we show the state of the field of Mediator study with a focus on the critical
kinase module. In the following chapters, we used siRNA knockdowns to investigate the
roles of the highly-conserved core subunit MED31 and the kinase module subunit
MED12 in directing cell state in human adult-derived mesenchymal stem cells harvested
from either bone marrow or adipose tissue. Knockdown of MED31 resulted in a decrease
in self-renewal based on cell assays and monitoring of gene expression and lipid vesicle
formation. MED12 knockdown has produced similar results, but a potential interaction
between MED12 and the master regulator of adipogenesis, PPARG, has been revealed
through the application of delayed knockdown assays. These studies seek to expand our
current understanding of stem cell behavior and how it relates to the critical Mediator
complex in order to further progress toward stem cell therapies. In our final chapter, we
show bioinformatics techniques that are rapidly transforming the field of biology that will
also greatly impact the study of the Mediator complex in human stem cells.
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CHAPTER 1
INTRODUCTION

1.1
1.1.1

Mediator and Gene Expression

Background
Our understanding of genomics and transcriptomics has advanced considerably in

the last thirty years. The Human Genome Project, exponential increases in computing
power, and the advent of next-generation sequencing have formed a solid foundation
upon which to study the transcriptome: the gateway between the potentiality of genomic
information and the actuality of cellular protein expression. Regulation of cell typespecific transcription is the key to that gateway, and the keeper of the key is the Mediator
complex. The Mediator complex is a highly conserved transcriptional regulatory complex
composed of many subunits divided into four modules, and it facilitates the convergence
of environment, signaling cascades, cell type-specific transcription factors, and core
transcriptional machinery to control cell state1–3. Mediator’s activity is associated with
recently characterized super-enhancers and their interaction with Mediator’s four
modules.
Perhaps the most poorly understood aspect of Mediator is its kinase module
composed of the subunit 12 or 12-like (MED12/L), subunit 13 or 13-like (MED13/L),
cyclin dependent kinase 8 or 19 (CDK8/19), and Cyclin C (CCNC). The final step in
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deciphering Mediator’s role in cell fate determination may lie in the greater
understanding of this enigmatic module. Stem cells offer a unique opportunity to delve
deeper into the role of Mediator and the kinase domain as these cells are normal, selfrenew, and differentiate4,5. Despite their incredible clinical relevance, particularly in the
fields of regenerative therapy and tissue engineering, there are still too many unanswered
questions that hinder their widespread clinical deployment, including questions about
how the environment, signaling pathways, transcription factors, and Mediator work
together to drive self-renewal and differentiation toward specific lineages. This
introduction will describe the Mediator complex, its association with super-enhancers, its
kinase module, and the kinase module’s role in controlling cell state and lineage
commitment. The discussion of the kinase module will include its structure, function,
association with disease, and role in regulating cell type specific transcription. Finally,
this introduction will identify gaps that remain in our current understanding of the kinase
module and point to those as opportunities for continued exploration.
1.1.2

The Mediator Complex
In 1990, around the time that the Human Genome Project was beginning in

earnest, Roger Kornberg’s lab at Stanford University stumbled upon a phenomenon while
studying transcription activation in S. cerevisiae. The work involved the potent activator
GAL4-VP16 (a hybrid protein composed of GAL4’s DNA-binding domain and the
activator portion of the herpes simplex VP-16 protein) and its in vitro inhibition of T-rich
binding factor. GAL4-VP16 was responsible for activating genes with GAL4 binding
sites while T-rich binding factor activated genes possessing thymine-rich regions.
Reasonably, neither activator should have interfered with the activity of the other unless
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an unknown coactivator was also required to complete the activation, and this coactivator
was acting as a limiting reagent due to its low availability. This squelching between the
two activators was relieved when S. cerevisiae protein fractions were added, indicating
that there was indeed a novel coactivator at work. Neither RNA polymerase II (RNAP II)
nor the general transcription factor TFIID proved to be this coactivator, and so the
mysterious factor was at once named the Mediator of RNAP II Transcription, describing
its observed function in the transcriptional process6,7 (for a more extensive history of
Mediator’s discovery, see review by Kornberg)8.
Over the next two decades, the Mediator complex was found to be universally
conserved throughout all eukaryotic organisms while completely absent in prokaryotes.
Eukaryotes, being far more complex than prokaryotes, owe their incredible complexity to
the regulation of gene expression provided, in large part, by the Mediator complex8.
Mediator is a large, 1 million Dalton8 protein complex composed of between 20-30
subunits depending on species3, and is arranged in four distinct modules: head, middle,
tail, and kinase9. Bioinformatic and biochemical analyses have identified most of the H.
sapiens Mediator subunits as similar in sequence, structure, and function to those found
in S. cerevisiae and D. melanogaster, indicating a high degree of sequence conservation
across eukaryotic species10 (Figure 1-1).
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Figure 1-1: Structural differences between S. cerevisiae (Yeast) and H. sapiens
(Human) Mediator complex. Shared and highly conserved subunits are shown in blue,
while additional subunits that exist in humans but not yeast are highlighted in orange.
This includes subunits that can substitute for each other in the kinase domain,
including CDK8/CDK19, MED12/MED12L, and MED13/MED13L.
1.1.3

Mediator and Super-Enhancers
In the past ten years, super-enhancers have been characterized as clustered

enhancers whose combined influence over the cellular transcription program is greater
than other known gene regulatory elements. The complexity and specificity of superenhancers make them critical components of identifying and characterizing cell typespecific genes. Super-enhancers were initially defined in embryonic stem cells by Whyte
et al. in 2013 as genomic elements occupied by 1) a significant number of cell typespecific transcription factors such as OCT4, SOX2, and NANOG, 2) an abundance of the
histone mark H3K27Ac, and perhaps most importantly, 3) the Mediator complex11.
Traditionally, enhancers have been defined as regions of DNA spanning only a few
hundred base pairs to which transcription factors bind. These elements occur with a
frequency of one every 3,000 to 30,000 bases and are responsible for regulating the
expression of a corresponding downstream gene by helping to recruit RNAP II to the
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gene’s promoter12. The unique feature of super-enhancers is the high level of Mediator
occupancy along with cell type-specific transcription factors when compared to typical
enhancers. Because of this, the identification of super-enhancers hinges primarily on the
presence of MED1, the largest and most highly conserved of the Mediator core
subunits11. Using chromatin immunoprecipitation sequencing (ChIP-seq), enhancers are
ranked by their MED1 enrichment and are plotted against the MED1 signal. All
enhancers beyond the inflection point—where the slope of the generated line graph
equals 1—are deemed super-enhancers and further investigated for co-occupancy by
other identifiers13. Given the role of Mediator as a bridge between cell type-specific
transcription factors and the transcriptional machinery, the detection of Mediator at the
enhancer and promoter of cell type-specific genes confirms DNA looping14. In addition,
it further identifies the promoter of a specific super-enhancer target gene (Figure 1-2),
making Mediator a significant factor in identifying cell type-specific gene profiles and
understanding transcriptional control that defines cell state11,15–20.
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Figure 1-2: Top: Linear representation of a super-enhancer. Grey ovals represent
DNA-bound transcription factors and orange circles represent the histone mark
H3K27Ac with the gene promoter potentially located over 10 kilobases downstream
of the super-enhancer. Bottom: DNA looping mediated by the Mediator complex and
Cohesin leading to the expression of the downstream gene14.
Understanding Mediator’s role in occupying enhancers and super-enhancers
began as early as 2010 when Kagey et al. used shRNAs to reduce expression of Mediator
and Cohesin—a protein complex involved in looping chromatin. The results of this study
indicated a loss of pluripotency in murine embryonic stem cells (mESCs) following the
knockdown of several Mediator subunits, most of the Cohesin subunits, and the Cohesin
loading complex subunit Nipbl. ChIP-seq analysis revealed that Mediator and Cohesin
co-occupied both the enhancers and promoters of key mESC regulators pou5f1 (the gene
encoding OCT4) and nanog, indicating that Mediator was interacting with distant
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enhancers and promoters simultaneously. Chromatin Conformation Capture (3C) assays
further confirmed DNA looping between these enhancers and promoters, supporting a
model for Mediator in which the complex reaches across a 3-dimensional chromatin
landscape to activate the expression of stem cell transcription factors and cell typespecific genes14. This work was later confirmed and expanded on in a series of
publications from other laboratories21–25.
In 2013, Whyte et al. performed ChIP-seq for OCT4, SOX2, and NANOG in
murine embryonic stem cells and observed yet another novel pattern in genome
occupancy. Of the 8,794 sites that were co-occupied by all three transcription factors, 231
of those sites were also occupied by MED1 at levels at least ten-times higher than typical
enhancers. In addition to patterns of transcription factor and co-factor occupancy, superenhancer-associated genes have higher rates of expression than genes associated with
typical enhancers. To demonstrate this, a luciferase assay was performed where pou5f1
was incorporated into either a cloned region from a typical enhancer or a super-enhancer.
This study revealed at least a 3-fold increase in pou5f1 expression when coupled with the
super-enhancer region compared to a typical enhancer region. Conversely, expression of
genes associated with super-enhancers was found to be reduced by 0.5-fold in the
absence of OCT4 or MED12, showing that super-enhancer regulation is indeed
dependent on the presence of key transcription factors and Mediator11.
Work in the same year—also performed in the lab of Dr. Richard Young at the
Whitehead Institute—expanded the search for super-enhancers beyond murine embryonic
stem cells. Hnisz et al. performed ChIP-seq for RNAP II and RNA-seq to monitor all
transcripts, and their data revealed that super-enhancers are enriched for both RNAP II
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and transcript with signals that are at least 24 times greater than those observed for
typical enhancers. These data support the evidence initially provided by Whyte et al. that
super-enhancer-associated genes are transcribed at higher levels. Finally, H3K27Ac
histone marks were measured using ChIP-seq to identify super-enhancers in 86 human
cells and tissue samples ranging from adipose and aorta tissue to small intestine and
thymus tissue18. This line of exploration revealed that super-enhancers are not a unique
feature of mouse and human ESCs but are indeed found in a host of cell types where they
are associated with master transcription factors such as MYOD1 (myoblasts) and PPARG
(adipocytes). Genome-wide association studies revealed that non-coding single
nucleotide polymorphisms (SNPs) that are associated with phenotypic traits also occur
disproportionately in super-enhancers. Some non-coding SNPs identified in superenhancers are linked with human diseases such as Alzheimer’s disease and type 1
diabetes, and cancers like pancreatic cancer and colorectal cancer. Such research has
further elucidated the importance of super-enhancers not only in the regulation of cell
type specificity, but also in the onset and progression of disease and oncogenesis18.
Given the interaction of Mediator with transcription factors, its regulation of cell
type-specific gene expression, and its intimate relationship with super-enhancers,
Aranda-Orgilles et al. sought to better understand the role of Mediator’s transient kinase
module in the regulation of cell state; namely MED12’s role in the maintenance of
hematopoietic stem cells (HSCs). First, MED12 knockouts were induced in mouse
embryos, resulting in mortality of all knockout mice within a month. The knockdout of
MED12 also reduced the growth of bone marrow and thymus tissue in these mice
compared to the untreated control. Considering the interdependence of the kinase module
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subunits, separate knockouts of MED13, CDK8, and CCNC (each discussed in further
detail later) were performed in murine HSCs but none could replicate the severity of the
MED12 knockout. This suggested MED12’s critical importance in maintaining HSC
viability. The expression of HSC-specific genes decreased in the absence of MED12
which indicated a role in regulating cell type-specificity. MED12 ChIP-seq was
performed in human HSCs, and 84% of the sites found to be occupied by MED12 were
located more than 10 kilobases from promoters. MED12 co-occupied genomic regions
along with the enhancer-associated histone mark H3K27ac and the transcription factors
RUNX1, FLI1, GATA2, and ERG. MED12 also occupied super-enhancers associated
with hematopoietic-specific genes26. This line of research revealed that beyond the
interaction of Mediator’s core with super-enhancers and promoters, Mediator’s foursubunit kinase module is also quite active on its own in genome-wide transcription
regulation and so deserving of more in-depth study.
Despite all the previous findings, the exact mechanism for how signaling factors
efficiently interact with transcription factors scattered across the enhancers and superenhancers of the genome remained poorly understood. More recently, Zamudio et al.
initiated studies to determine how signaling factors, namely ß-catenin, interacted with
chromatin, transcription factors, and Mediator to form condensates: three-dimensional
pockets of enhancers and super-enhancers all interacting together to drive cell typespecific gene transcription. RNA-FISH was performed to monitor the location of nanog
transcripts and IF staining was used to confirm that the signaling factors ß-catenin,
STAT3, SMAD3, and coactivator MED1 all localize to regions of nanog involved in
activating transcription. ChIP-seq analysis confirmed that all four factors interact with the
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nanog-associated super-enhancer27. The model for ß-catenin’s interaction with the nanogassociated super-enhancer established by this research serves as an explanation for how
signaling factors can simultaneously influence the expression of several genes important
for the maintenance and development of stem cells.
Taken together, these studies over the past ten years indicate a cooperativity
between chromatin structure in the form of super-enhancers, the Mediator complex, and
Mediator’s kinase module that is integral for the direction of cell type-specific gene
transcription. Now that Mediator and super-enhancers form part of the foundation of
transcription regulation, the outstanding question from our existing information involves
the extent to which Mediator’s kinase module plays a role in the overall process of cell
type determination, either in regulating Mediator itself, or as independent coactivating
subunits, or both.
1.2
1.2.1

Mediator’s Kinase Module and Role in Disease and Development
The Mediator Kinase Module

The Mediator complex exists in two forms: The Mediator complex with the
kinase module (30 subunits) and the core Mediator (26 subunits), which lacks the foursubunit kinase module. The 600 kDa kinase module is stable and able to exist and
function independently of the core Mediator complex and can transiently associate with
the core complex through MED138,37. The structural and functional aspects of the kinase
module, including information on paralogs of the kinase module subunits and the
importance of kinase activity in transcriptional regulation, is described below.
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Structure and Function
A tightly organized network of both physical and functional subunit interactions
maintains the structural integrity of the kinase module. Detailed studies of this complex
structure have revealed the subunit organization within the kinase module, adding critical
insight into the mechanism of CDK8’s enzymatic activity. Specifically, early electron
microscopy analysis in S. cerevisiae showed the kinase module structure having two bent
protruding ends, identified as CDK8-CCNC, MED13, and a central globular protein,
MED12. This model correlated with the previously observed human kinase module
structure, with both models confirming the connection of the kinase module to the
Mediator core through MED13 (Figure 1-3)28.

Figure 1-3: Mutually exclusive paralogs of subunits from the Mediator kinase
domain. These paralogs, CDK19, MED12L, and MED13L, are replaced by CDK8,

13
MED12, and MED13 respectively under specific conditions, although the full details
of how and why remain unknown.
The association of the kinase module through MED13/MED13L allows for the
adoption of different conformations and reversible interactions not just with the core
Mediator but with other factors involved in transcription and cell state regulation29. In
addition, physical interactions between kinase module subunits and the core Mediator
leads to the adoption of different complex conformations, which also plays a role in
activating CDK8 kinase activity. Compiling data from different studies, it has been
shown that CDK8 kinase activity is activated through a series of sequential steps: the first
is the binding of CDK8 to its cyclin partner, Cyclin C (CCNC), resulting in partial
activation of CDK8. This is then followed by the binding of MED12 which results in the
final necessary conformational change30,31. Biochemical studies revealed that CCNC
possesses a surface groove that acts as a MED12 docking site. Mutations in either CCNC
or the MED12 interface located at the N-terminal of MED12 leads to the dissociation of
CCNC-CDK8 from the core Mediator complex followed by impaired kinase activity of
CDK832. These findings suggest that the MED12-CCNC binding interface serves as an
anchor that also activates CCNC-CDK8.
Kinase Module Paralogs
Although highly conserved as a complete complex, the kinase module in
vertebrates is unique and more complex when compared to the core complex as three of
the four subunits have paralogs. CDK8 can be replaced by CDK19, MED12 can be
replaced by MED12L, and MED13 can be replaced by MED13L33,34. The replacement of
these subunits by their paralogs is mutually exclusive, meaning that the kinase module
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can possess either MED12 or MED12L but not both subunits simultaneously, leading to
eight different forms of the kinase module subunits (Figure 3)35.
CDK19, the homolog of CDK8, shares a 91% sequence homology with CDK8.
There is an especially high degree of sequence conservation in the kinase activity domain
and cyclin binding domain, with more divergence in the C-terminal sequence. The high
degree of similarity suggests that CDK8 and CDK19 have overlapping functions and that
one may be able to compensate for loss or absence of the other as it relates to kinase
activity. For example, isolation and purification of CDK8/CDK19 interacting proteins
demonstrates that both CDK19 and CDK8 interact with PRMT5 during repression of
transcription in HeLa cells (Tsutsui et al. 2013). However, given that the tail portion of
CDK8/CDK19 interacts with transcription factors and cofactors, the difference in the Cterminal sequence suggests that CDK8 and CDK19 more likely regulate different
transcriptional programs33,36. Supporting this is the fact that CDK8 and CDK19 are
differentially expressed across tissues, with CDK19 expression restricted to prostate,
testis, thymus, and salivary glands, while CDK8 is expressed more ubiquitously across
tissues37.
Homology studies reveal that MED12 and MED12L share a 67% sequence
identity, sharing two of four protein domains: PQL (proline/glutamine/leucine-rich) and
OPA (C-terminal opposite paired domain). Interestingly, according to the human protein
atlas, after analyzing approximately 37 human tissue samples, MED12L is found to be
most highly expressed in the brain while MED12 is expressed ubiquitously in all
tissues38,39 (for more information about the human protein atlas visit proteinatlas.org).
Though they only share similarity in two of the domains, there does appear to be
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functional redundancy between MED12 and MED12L. For example, a study by Vogl et
al. suggests MED12 and MED12L have the same binding sites for SOX10, which is an
essential component of the transcriptional network that regulates the development and
terminal differentiation of myelinating glia. From a series of pull-down experiments of
MED12/MED12L and SOX10 proteins, it is evident that the C-terminal region of both
MED12 and MED12L interact with SOX10. This discovery lead to the assumption that
both proteins have the same function in the regulation of transcription during the
differentiation of myelinating glia40. However, there is currently little research in this
area, making it difficult to evaluate the complete functional redundancy between MED12
and MED12L.
Finally, MED13L shares a 51% sequence similarity to MED1341 and they both
serve to link the kinase module to core Mediator by associating with middle module
subunits, MED14 and MED1942. Notably, this interaction of MED13/MED13L with core
Mediator is regulated by SCF-FBW7 ubiquitin ligase through the proteasomal
degradation of MED13/MED13L. Immunoprecipitation and in vitro ubiquitylation assays
reveal that MED13/MED13L are directly ubiquitylated by SCF-FBW7 in vitro43. This
degradation of MED13/MED13L prevents the kinase module from associating with the
core complex suggesting that MED13/MED13L serves as an anchor for the kinase
module. Interestingly, MED13L, but not MED13, associates with MED26, indicating
there may be unique functions for each subunit. When co-purified, MED13L is
accompanied by a high abundance of MED26; however, MED13L is not present in
MED26 isolations. This association is found to be specific to MED13L, as the same set
of pull-down assays does not show a robust association between MED13 and MED2642.
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According to the human protein atlas, MED13L is primarily expressed in heart and brain
while MED13 is expressed in all human tissues. More recent evidence supports previous
studies indicating that mutations in med13l are associated with neurodevelopmental
defects and heart diseases44,45. Knockdown and conditional knockout studies of MED13
in murine zygotes suggest that MED13L can partially substitute for MED13 and function
during the development of embryo46. This study demonstrates that MED13 is required for
both transcriptional activation and repression during zygote genome activation, as
demonstrated through the up- and downregulated transcripts observed in MED13knockdown embryos. Furthermore, med13 knockout embryos showed arrested
development post-implantation. MED13L compensated for MED13 function during the
OET (oocyte to embryo transition) enough to support embryo development to the
blastocyst stage during preimplantation in med13 knockout murine zygotes. Clearly, the
functional compensation of MED13 by MED13L is limited in context, as evident by its
lack of compensation during post-implantation development and other studies showing
mutations of MED13/MED13L that lead to disruptions of cellular functions resulting in
respective disorders47,48.
Together, studies surrounding the kinase module and each of the seven subunits
indicate that the kinase module of the Mediator complex can present itself in many forms
by changing its subunit configuration to diversify its function. Although it appears that
there is some amount of functional overlap between paralogs, there is no complete
functional redundancy for any of these kinase module subunits. Some of these paralogs
may in fact play different roles in development and cell-type specific transcription
programs. In addition, individual genetic mutations of kinase subunits leads to embryonic

17
lethality in mice and many human disorders with clear developmental
disruptions26,46,49,50. In addition, research to date excludes the possibility of complete
functional redundancy among the paralogs as they failed to substitute for their paralogous
subunits (except for the partial functional compensation of MED13 by MED13L in
murine zygote development as described in MED13 paralog section) when the other is
genetically disrupted. The mutually exclusive nature, the unique expression profiles, and
the relative functional contribution of each kinase module paralog still requires more
thorough investigation to understand the structural interactions and functional
relationships within the kinase module and what role each subunit plays in human
development and disease.
Kinase Module and Transcriptional Control
The kinase module functions as both an activator and repressor of gene
transcription, making the study of the module that much more complicated. Initial
functional studies revealed a repressive function for the kinase module in S. cerevisiae
where the Mediator core, together with the kinase module, repressed transcription and the
Mediator core alone enhanced activator-dependent transcription51. Early electron
microscopy and subsequent functional studies in human HeLa cells showed that the
kinase module repressed transcription by preventing the binding of RNAP II to Mediator
thereby blocking the formation of the PIC-scaffold complex. This inhibition was
achieved via multiple mechanisms, including kinase-independent regulation of MediatorRNAP II interaction30, kinase-dependent inactivation of TFIIH by phosphorylation51, and
gene silencing through the recruitment of histone methyl-transferases29. Later,
biochemical and molecular studies supported the view that the kinase module has a
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context dependent role in both gene repression and activation11,52. It now appears that
when the Mediator core is absent, the kinase module acts to inhibit core Mediator
function within the pre-initiation complex (PIC)29,52. Furthermore, the kinase module
appears to mediate transcriptional activation through ncRNA-a (noncoding RNA-a, a
class of ncRNAs which activate neighboring genes) by interacting with MED12 and
chromatin53. Finally, a new role for the kinase module in the regulation of transcription
elongation has been reported where the kinase module appears to coordinate with positive
transcription elongation factor b (P-TEFb) by regulating its kinase activity. ChIP analysis
and genome occupancy profiles of elongation factors in human cells indicate that CDK8
orchestrates key events in the formation of a functional elongation complex. CDK8 is
required for RNAP II dependent elongation by phosphorylating the C-terminal domain of
RNAP II as they demonstrate that RNAP II elongation is impaired upon knockdown of
CDK854. This study also suggests that the kinase module may facilitate the interaction of
P-TEFb with core Mediator to regulate RNAP II phosphorylation and transcription
elongation. These studies represent a marked advance in our understanding of how the
kinase module acts to both repress and promote gene expression, while also revealing
additional questions about the role the kinase module has as part of the core Mediator
complex in regulating transcription.
Although the precise mechanism that regulates the reversible association of the
kinase module with core Mediator is not clearly understood, a few studies offer some
insight into why the regulatory association of the kinase module with core Mediator
occurs. Initial clues were provided by studies in yeast suggesting that the reversible
association between the kinase module and core Mediator existed as way of regulating
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the output of signaling-dependent transcription. Similarly, later studies in mammals
suggest that specific cellular signals and signaling pathways regulate Mediator-kinase
module association. For example, an in vivo study by Mo et al. in human HeLa cells
showed that in response to Ras signaling, the repressed promoter of the C/EBPβ is kinase
module-bound whereas, upon activation, the kinase module is lost55. Another study by
Pavri et al. demonstrated the switch from inactive to active Mediator executed by PARP1 during retinoic acid (RA)-induced gene expression in vivo. ChIP analysis of promoter
occupancy in PARP-1 present and absent cells shows that in the absence of PARP-1,
Mediator did not attain its active conformation (accompanied by loss of kinase module)
upon RA induction as evidenced by the retention of CDK8 after RA treatment56.
Although these studies do not prove the exact mechanism for what triggers the kinase
module to dissociate from the core, they do suggest that the kinase-containing Mediator
complex requires an interaction with other factors in order to detach from the kinase
module and adopt the conformation required to facilitate transcriptional activation.
Indeed, Davis et al. demonstrated mechanistic evidence of kinase module dissociation
involving SCF-FBW7 ubiquitin ligase mediated proteasomal degradation of
MED13/MED13L, which anchors the kinase module to core Mediator43. A recent study
by Youn et al. also demonstrated that the Mediator complex in mouse liver undergoes
dynamic physiologic regulation through nutrient signaling-dependent downregulation of
the kinase module to core Mediator. This dissociation and degradation of the kinase
module is induced by SCF-FBW7 E3 ligase57.
Finally, the Mediator kinase module has been implicated as a gene regulator in
physiological processes from development and differentiation to the maintenance of cell
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fate and function. Several genetic studies have revealed critical roles for kinase subunits
in regulating signal-dependent gene expression during development49,58,59. In mice,
kinase module subunits are found to be critical in early development, as evident by
embryonic lethality resulting from mutations in kinase subunits. For example, embryo
implantation failure is observed when CDK8 is inactivated through gene trap insertions,
suggesting that CDK8 is necessary for preimplantation of mouse embryos50. CCNC
knockout murine embryos failed to survive past implantation due to severe
developmental retardation and an underdeveloped placental layer64. MED12 mutant and
knockout embryos failed to survive later embryonic stages as they suffered from acute
defects in developmental processes including neural tube closure and heart formation55.
Several studies show that these developmental disruptions stem from defects in key
developmental signaling pathways, including Wnt, Notch, mTORC1, and TGFβ. The
kinase module subunits are found to be involved in expression of signaling pathway
target genes and when mutated, lose their ability to activate or repress expression of
required target genes for respective signaling pathways, leading to impaired responses of
signaling pathways as illustrated by a growing number of developmental disorders. For
example, loss of CDK8 in murine embryos is shown to disrupt Wnt target gene
expression58. Mutant MED12 murine embryos showed aberrant Wnt/β-catenin target
gene expression, indicating that MED12 is essential for Wnt signaling during
embryogenesis where MED12 mutant embryos recapitulated phenotypes similar to those
observed in the absence of β-catenin55. Recently, CDK8/CDK19 has been shown to have
a role in negatively regulating Notch 1 signaling, a developmental pathway which
regulates self-renewal and differentiation in several cell types including stem cells60.
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Kinase subunits have also been linked to TGFβ, a developmental signaling pathway
which regulates cell proliferation, differentiation, cell fate, and apoptosis. CDK8-CCNC
plays a critical role in regulation of SMADS in TGFβ driven transcriptional responses by
limiting the SMAD2/3-dependent induction of mesodermal cell fate in response to TGFβ
signaling61. Recently, a study by Youn et al. demonstrated that when mice were fasted
and refed, the kinase module dissociated and degraded upon nutrient activation of
mTORC1 in mouse livers. This dissociation and degradation of the kinase module is
necessary for the induction of lipogenic gene expression because
genetic/pharmacological inhibition of mTORC1 in the fed state restores the kinase
module suggesting that the kinase module plays a role in repressing lipogenic gene
expression. In addition, genetically insulin resistant and obese mice in the fasted state
showed elevated levels of lipogenic gene expression and loss of the kinase module was
reversed following mTORC1 inhibition61. In agreement with these studies, the kinase
module has been involved as the terminal factor of cell signaling pathways due to its
representation as a final and functional target for transcription factors. Together, these
studies imply a highly targeted role of individual Mediator subunits in the regulation of
cell state and lineage commitment through the regulation of developmental signaling
pathways.
Kinase Activity
Finally, one of the most important and highly conserved functions of the kinase
module is its kinase activity. The best characterized of these activities is the kinase
module’s phosphorylation of the C-terminal domain of RNAP II during transcription
initiation, elongation, and RNA processing3. Human CDK8 appears to negatively

22
regulate transcription by phosphorylating TFIIH51, while inhibition of CDK8 kinase
activity suppresses the RNAP II CTD phosphorylation thereby preventing elongation of
transcription62. Despite the requirement for CDK8 and CCNC to interact and bring the
kinase module together, the CDK8-CCNC interaction is not sufficient for CDK8 kinase
activity. In the past two years, a series of studies by two different labs have provided
evidence that MED12 is required for CDK8 kinase activity63,64. With a combination of
Hi-C and cryo-EM studies along with knockdown studies in murine embryonic stem
cells, MED12 knockdown cells showed acute depletion of Mediator and RNAP II,
indicating that MED12 is required for proper phosphorylation of RNAP II. Another
recent study by Klatt et al. described the binding location of MED12 and CDK8-CCNC
dimer providing insight into activation of CDK8 by MED12. In vitro biochemical and in
vivo studies together with cross-linking coupled with mass spectroscopy, demonstrated
that the N-terminal of MED12 wraps around CDK8 at its T-loop to form an activation
helix, which activates the enzymatic activity of CDK864. With MED12 now known to
activate CDK8 as a kinase, the association of MED12 with the CDK8-CCNC dimer
provides a critical element of regulation and prevents uncontrolled and inappropriate
substrate targeting.
Overall, the genetic and biochemical analysis of the kinase module is consistent
with the functional studies indicating a role for this unique module in both gene
activation and repression. The kinase activity of CDK8 is required for activatordependent transcription and has been shown to direct multiple steps in transcription
including initiation, elongation, and re-initiation. Although several studies have begun to
shed light on the signaling and mechanistic role for the kinase module and Mediator core,
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there is still much to be explored. Involvement of kinase subunits in many physiological
processes and pathways proves the complexity and the functional implications of the
kinase module subunits either individually or as a complete structure. The significant
functional involvement of the Mediator kinase module in regulating aspects of
transcription has a significant impact on human development as illustrated by an
increasing number of diseases and developmental disorders that have been associated
Mediator subunit mutations (Table 1-1).
1.2.2

The Kinase Module and Human Diseases
The Mediator kinase module is a critical component of the transcriptional

machinery required for proper regulation of gene expression and lineage commitment of
cells during development and tissue differentiation1,6,8. Kinase module subunits, as part of
the Mediator complex, have been linked to many key developmental and oncogenic
signaling pathways including Wnt, mTORC1, EGF, SHH, and Notch10,49,65,66. Alterations
of individual subunits of the kinase module have been associated with developmental
defects and diseases including Lujan syndrome, schizophrenia, breast and uterine
cancers, and cardiovascular diseases67. Studies have found that the kinase module
subunits are direct targets of genetic alteration in human tumors and specifically,
MED12, the largest subunit of the kinase module, has been consistently implicated in
many female cancers and cognitive developmental conditions. Research indicates that it
is the role of MED12 in regulating the kinase activity of the module that leads to a
number of these outcomes68. Specific roles for each of the kinase module subunits in
development and disease can be found in Table 1-1.
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Table 1-1: Currently known roles for Mediator kinase subunits in development or
disease. Most cancers noted in this table were previously compiled and reviewed by
Clark, Oldenbroek, & Boyer69.
Subunit

Role

CCNC

Multiple deletions associated with T-cell acute lymphoblastic leukemia;
function as a tumor suppressor60,70
Deletion associated with osteosarcoma; function as an inhibitor of cell
growth71
Regulation of adipogenesis72
G0 to G1 transition in CD34+ cord blood cells73

CDK8

Phosphorylation of TFIIH to activate transcription51
Phosphorylation of E2F to activate transcription74
Phosphorylation of RNA Pol II C-terminal domain to repress
transcription75,76
Maintenance of ESC pluripotency mediated by MYC protein77
Colorectal cancer oncogenesis58,78,79
Melanoma oncogenesis80
Breast tumorigenesis81
Endometrial cancer tumor suppression82
Alzheimer’s disease83

CDK19

Upregulated in prostate cancer84
Intellectual disability85
Epileptic encephalopathy84

MED12

Designated a cancer driver gene86,87
Uterine leiomyoma oncogenesis68,88,97–101,89–96
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Breast fibroadenoma oncogenesis and phyllodes tumorigenesis102–107
Prostate cancer oncogenesis108–110
Interaction with NANOG and SOX2 C-terminals to regulate ESC
pluripotency111
Interaction with Wnt/β-catenin to recruit core Mediator to target genes49
Interaction with PRC1 to repress differentiation genes during
pluripotency112
Super-enhancer-associated co-activator26
Maintenance of HSC viability26
Neural development in zebrafish113–115
Interaction with SOX10 in myelinating glia40
Development of epithalamus in zebrafish116
FG syndrome117
Lujan syndrome118
Ohdo syndrome119
MED12L Designated a cancer driver gene120
Interaction with SOX10 in myelinating glia40
MED13

Neurodevelopmental disease121
Breast cancer oncogenesis122
Regulation of early embryogenesis46
Interaction with Smad7 to regulate myogenesis123

MED13L Congenital heart defects41,124
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1.2.3

The Kinase Module and Stem Cells
All cells in an adult human have the same 3 billion base pair genome, but it is

how that genome is expressed that determines whether a cell becomes a myocyte, an
osteocyte, a neuron, etc. Stem cells are both able to clone themselves and able to become
specialized cell types by pursuing one of a number of possible cellular lineages.
Pluripotent stem cells, such as embryonic stem cells in the blastocyst stage of embryonic
development, are ultimately committed to cells of either the endoderm, mesoderm, or
ectoderm lineage4. Gene regulation is tightly controlled in order to ensure proper
transcription for healthy organismal development. Aberrant gene expression is implicated
in a multitude of developmental defects and disease and would be more rampant if not for
the highly specialized, complex method for cell type-specific transcriptional control125,126.
The unique properties of stem cells to both self-renew and differentiate under controlled
laboratory conditions allows for the effects and functional characterization of deliberate
perturbations in the regulation of gene expression4. This includes altering the function
and expression of the general transcription factors (GTFs) that assemble the transcription
pre-initiation complex on gene promoters, activators and repressors that bind to gene
regulatory elements located upstream or downstream of promoters, and the essential coactivator of cell type-specific genes like the Mediator complex. The fate of any stem cell
is ultimately determined by regulating the transcription of specific genes, a feature
largely facilitated by the Mediator complex.
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Stem cells are categorized based on their differentiation potential. Totipotent stem
cells have the potential to become any cell type in the body including extraembryonic
tissue; an example of which is the zygote4,127. Pluripotent stem cells, such as embryonic
stem cells in the blastocyst stage of embryonic development, are committed to cells of
either the endoderm, mesoderm, or ectoderm lineage128. Adult stem cells are a
multipotent cell type that can be found in umbilical cord blood and tissue, bone marrow,
adipose tissue, and several other fully developed organs129,130. These cells have a more
restricted developmental pathway and, in the body, will only become cells of that tissue
or organ. Of course, the potential for stem cells to differentiate allows them to change
their transcription program in response to the environment. In this way, a stem cell is a
progenitor possessing a certain identity, and by changing its transcription program, it can
assume a new identity as a differentiated somatic cell. Despite different levels of
differentiation potential possessed by different classes of stem cells, all stem cells share
the ability to self-renew4. We will begin this section by exploring stem cell self-renewal
and the role of the Mediator complex kinase module in this process, followed by the
kinase module’s regulation of differentiation down the various possible lineages.
Kinase Module and Self-Renewal
Self-renewal is the process by which stem cells replicate themselves to maintain a
stable population of undifferentiated clones. For individual stem cells, self-renewal and
differentiation are mutually exclusive in that lineage commitment down a differentiation
pathway alters a stem cell’s gene expression profile away from self-renewal permanently.
If a stem cell is not self-renewing, it is differentiating, and vice versa131—until the stem
cell reaches quiescence, temporarily halting further self-renewal132.
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Work by Miyata et al. revealed that, when exposed to cytokines, human cord
blood CD34+ cells in the quiescent G0 phase of the cell cycle expressed CCNC at a higher
level compared to cells in the more growth oriented G1 phase. This led them to perform
an shRNA-mediated knockdown of CCNC in the cord blood cells which resulted in an
increase in G0 cells in their culture population as determined by Hoechst and Pyronin Y
staining. It must be noted that the knockdown of CCNC did not increase differentiation.
Interestingly, in the absence of CCNC, cord blood cells were able to maintain expression
of CD34 at higher levels than control cells through up to 4 weeks of cell culture, possibly
due to the induced quiescence keeping the cells in a protracted immature state73.
Like CCNC, CDK8 has also been shown to play a role in stem cell self-renewal.
Murine ESCs showed a significant reduction in both transcript and protein expression of
CDK8 post-differentiation. Following this, an shRNA knockdown of CDK8 was
performed in murine ESCs which resulted in a loss of ESC pluripotency. This was
determined by the reduced expression of NANOG and OCT4, reduced alkaline
phosphatase staining, and reduced colony formation in these cells. Further study revealed
that CDK8’s regulation of pluripotency was at least partially mediated by MYC protein77.
Co-IPs were used to determine the interaction between MED12 and the Cterminal domains of NANOG and SOX2 in ESCs. Furthermore, an siRNA-mediated
knockdown of MED12 was performed in murine ESCs. NANOG transcript and protein
levels fell by as much as 65% in the absence of MED12 in addition to the onset of
spontaneous differentiation. This loss of pluripotency during MED12 knockdown could
not be rescued by a NANOG-expressing doxycycline system, indicating the requirement
for MED12 for proper differentiation. In ESCs undergoing differentiation, while the
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expression of NANOG, OCT4, and SOX2 decreased, MED12 expression increased 3.5fold. NANOG and MED12 co-occupy NANOG target genes during pluripotency, but this
co-occupancy ends during differentiation111. This work was later challenged by data
collected in a recombinant murine ES cell line expressing a hypomorphic MED12 mRNA
at low levels. Despite this, the absence of MED12 was embryonic lethal in mice, and this
was attributed to MED12’s interaction with Wnt/β-catenin signaling pathway for
recruiting core Mediator to target genes49.
ChIP-seq analysis conducted in murine ESCs revealed a small degree of
overlapping genome occupancy between CDK8, MED12, and the polycomb repressor
complex 1 (PRC1) subunit RING1B. PRC proteins are known regulators of embryonic
stem cell state. Of the identified MED12 targets, 21% were co-occupied by RING1B.
Furthermore, 80% of these regions occupied by MED12 and RING1B were also occupied
by MED1, indicating that the entire core Mediator was present at these sites. Gene
ontology identified these sites as genes necessary for differentiation and development. An
shRNA-mediated knockdown of RING1B in murine ESCs saw a marked decrease in
MED12 chromatin interaction. The inverse was not true in a MED12 knockdown
condition where MED12 recruitment to core Mediator was reduced in the absence of
RING1B, and Co-IP confirmed that MED12 and RING1B interact directly. Quantitative
PCR found that, in pluripotent murine ESCs, almost 600 genes were more highly
expressed in the absence of either MED12 or RING1B, showing a role for MED12 and
RING1B in development-associated gene repression during pluripotency; however,
further research indicated that MED12—not RING1B—was responsible for activating
development genes during murine ESC differentiation112.
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As discussed previously, MED12 is critical for maintaining HSC viability. After
performing MED12 knockouts in mice using a Cre recombinase system, a 75% decrease
in cell numbers was observed in the bone marrow and thymus of the MED12 knockout
mice compared to a control. A CFU assay revealed that HSCs lacking MED12 were
unable to form colonies, highlighting a failure in HSC self-renewal. Interestingly, the
researchers knocked out MED12 in an immortalized mouse embryonic fibroblast (MEF)
cell line and observed no significant changes in cell growth compared to a control. A
similar experiment in murine ESCs were able to maintain pluripotency markers and selfrenewal capability despite the absence of MED1226. These findings suggest that, although
different stem cells have similar properties such as self-renewal and differentiation,
potency and lineage commitment of different stem cell classes is governed by highly
specific regulators.
Finally, zygotes and other totipotent stem cells also offer an opportunity to
broaden our understanding of self-renewal. Microarray analysis revealed that, out of all
Mediator subunits, MED13 was the most highly translated Mediator subunit during
oocyte maturation with MED13L and MED12L ranking at second and third, respectively.
This high level of MED13 translation continues into the two-cell (2C) stage of embryo
development. Morpholino oligonucleotides were used to block MED13 translation at the
single-cell zygote stage 4 hours post-fertilization, and while the zygotes underwent
cleavage into the 2C stage, only 40% of tested embryos were able to advance to the 4C
stage. Those embryos that reached 4C halted thereafter. Performing the same experiment
6 hours after fertilization allowed 78% to advance to the morula stage. After ruling out
transcription and DNA replication failures as reasons for the MED13 knockdown’s
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effects, RNA-seq analysis revealed 1201 upregulated and 2203 downregulated genes in
the absence of MED13. RNA processing, cell cycle, transcription, protein catabolism,
and chromatin modification were among the categories of the downregulated genes
discovered during GO analysis46. Given that these sets of genes are important for
determining cell state, these results point toward the Mediator kinase module as an
integral cell state regulator.
Kinase Module and Differentiation
Differentiation is the process by which a stem cell alters its transcription program
in response to the external environment and internal regulation to commit to one of its
many potential lineages. In normal, healthy stem cells, differentiation is a permanent
epigenetic transformation that, once started, causes a stem cell to lose its potency and
self-renewal capacity while gaining specialized forms and functions important to the
operation of tissues and organs. Here we review some of the lineage commitments where
the kinase module has been shown to play a significant role to further support the critical
role of Mediator in directing cell fate and need for continued research in this area.
Adipogenesis:
Work by Song et al. involved screening adipocytes with shRNA libraries to
identify genes whose expression was altered during adipogenesis. CCNC and CDK19
were found to be downregulated while CDK8 was upregulated during adipogenesis.
CCNC and CDK19 expression in brown adipose tissue of 2-year-old mice was down to
25% of the expression levels present in 3-month-old mice. Conversely, CDK8 expression
was twice as high in the brown adipose tissue of older mice when compared to the
younger mice. Since brown adipose tissue is responsible for producing heat, groups of
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mice were exposed to either 4°C or 22°C conditions. The transcription levels of ccnc,
cdk8, and cdk19 mRNA were determined to be unaffected by these differences in
temperature; however, CCNC and CDK19 protein expression fell slightly while CDK8
rose in the 4°C group compared to 22°C. After performing siRNA knockdown of ccnc,
the expression of adipogenesis markers including PPARG, FABP4, and CEBPA fell
during the first 2 days of adipogenesis, but expression of these genes increased after 5
days to the levels in the control group. After switching to an inducible knockout system
for CCNC, cells undergoing CCNC knockout did not undergo adipogenesis and did not
express the previously tested adipogenic markers as well as a host of other genes
associated with brown adipose tissue, mitochondria, and lipogenesis. Retroviruses
expressing CCNC only partly rescued adipogenesis in CCNC knockout cells but did not
improve adipogenesis in cells unaffected by CCNC knockout. The most down regulated
pathway in the absence of CCNC was the PPAR pathway, a master regulator of
adipogenesis. PPARG-2 overexpression rescued both lipid vesicle formation and
adipogenic marker expression in CCNC knockout cells, showing that PPARG’s activity
does not depend on CCNC. C/EBPα, a co-regulator of adipogenesis along with PPARG,
could not rescue adipogenesis upon overexpression in CCNC knockout cells. Due to
C/EBPα being an important regulator of white adipose tissue, siRNA knockdown of
CCNC was also performed in 3T3-L1 cells, revealing a similar decrease in lipid
accumulation and adipogenic marker expression as was seen in brown adipose tissue72. In
summary, CCNC regulates adipogenesis by interacting with C/EBPα.
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Myogenesis:
Like adipogenesis, the process of differentiating into skeletal muscle tissue
involves interactions between kinase module subunits and transcription factors to achieve
proper regulation. MED12 and β-catenin are known to interact133, and β-catenin is active
during myogenesis134–136. Further research found that not only does Smad7 interact with
β-catenin to regulate myogenesis, but Smad7 also interacts directly with MED13. The
significance of this finding is that the Smad7:β-catenin complex could be responsible for
recruiting core Mediator to myogenesis-specific promoters via kinase module association
through MED12 and MED13123.
Osteogenesis:
Bone tissue is maintained by the actions of osteoblasts and osteoclasts.
Osteoblasts perform mineralization that increases bone density whereas osteoclasts resorb
bone matrix which decreases bone density. Initial research revealed that the inhibition of
CDK8/19 could interfere with the self-renewal capacity of bone progenitor stem cells by
virtue of the Wnt signaling pathway. Though bone formation was disrupted by CDK8/19
inhibition, it was through a mechanism independent of Wnt137. Later work tested the
effects of CDK8/19 inhibition on murine bone marrow macrophages, osteoblasts, and
osteoclasts. While inhibition did not affect macrophage and osteoblast self-renewal, it did
reduce the osteoclast differentiation of the macrophages and lead to significantly
decreased bone matrix resorption. Both effects were reversed by withdrawing the
CDK8/19 inhibitors. Expression of osteoclastogenic genes were downregulated in
macrophages exposed to CDK8/19 inhibition. Meanwhile, CDK8/19 inhibition increased
ALP activity in murine osteoblasts and boosted calcium deposition138. This research

34
demonstrates CDK8 and 19’s role in maintaining bone tissue by playing on the side of
osteoblast and osteoclast activity simultaneously. It is possible that all the kinase module
subunits are responsible for acting as both drivers and repressors to a certain degree,
especially given their relationships to oncogenesis.
Neurogenesis:
Due to the difficulty of studying mammalian neurogenesis directly, murine or
human stem cells and tissue, along with zebrafish models represent the primary means of
exploring this area of development and differentiation116. Research in this area began by
identifying mutations of MED12 (at that time referred to as TRAP230, or thyroid
hormone receptor-associated protein) that produced truncated MED12 protein, resulting
in zebrafish brain tissue that developed all the correct regions but failed to expand
anteriorly and posteriorly while also failing to form the forebrain and midbrain
ventricles113. Another mutation of MED12 was found to disrupt neural tissue
development in zebrafish, and the mutant embryos were rescued by the introduction of
wildtype med12 mRNA. In situ hybridization was used to determine that MED12 is most
active in the part of the zebrafish brain forming the ventricle lining. Overexpression of
MED12 lead to premature neuronal development and increased differentiation of
monoaminergic neurons but did not increase neuron differentiation overall114. MED12
was later found to interact with the intracellular domain of amyloid precursor protein
(AICD), a protein essential for brain development and function115. MED12 coactivates
tbx2b transcription which guides neural progenitor cells toward correct epithalamic
differentiation at a critical moment in brain development in zebrafish116. Beyond neurons,
MED12 and MED12L were also discovered to interact with SOX10 in order to direct the
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development of Schwann cells and oligodendrocytes, two types of glial cells that are
responsible for the formation of myelin sheaths that insulate neuron axons and accelerate
action potentials40.
1.3

Significance of Understanding Mediator’s Kinase Module

Nearly thirty years ago, a question about in vitro gene activation led to the
discovery of the Mediator complex. At once, this expanded our understanding of how
complex life can be achieved with relatively few genes. Since then, each answered
question has bred a multitude of further questions. Because of that, we now know how
near (or far) gene regulatory elements are from gene promotors, how Mediator reaches
across vast linear distances through the three-dimensional folding of chromatin to reach
those elements, and that super-enhancers work with Mediator to regulate cell typespecific gene transcription. The kinase module has expanded the complexity of this
regulatory relationship given its transient nature, and we are certain of the kinase
module’s subunit and paralog composition with CDK8/19 possessing kinase activity. It is
understood that each kinase module subunit plays an integral role in the module’s overall
stability, thereby enhancing its regulatory and kinase activity. Unfortunately, mutations in
these subunits have been implicated in a host of developmental disorders and diseases,
including many cancers. wherein lies the importance of proper kinase module functioning
to maintain healthy development and cell fate determination. Research is now branching
into the kinase module’s activity in the context of stem cell self-renewal and
differentiation.
Despite what we have learned, we still do not have a complete understanding of
how, precisely, the kinase module interacts with nuclear machinery and signaling
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molecules to drive cell state into a particular direction: either to maintain homeostasis or
to differentiate down the epigenetic landscape toward any particular lineage while
avoiding oncogenesis. Though we know several targets of kinase module interaction in
this context, we are far from knowing them all. A large focus has been placed on MED12
(warranted considering its importance in oncogenesis and development), and this has
elevated the profile of the individual subunit and that of the entire kinase module. While
this is bearing good fruit in terms of thorough research (ChIP-seq and genomeinteractions), more abundant fruit would be reaped by similarly thorough elucidation of
the other subunits and their interactions with each other. It must be stressed that there is
much about the paralogs (MED12L, MED13L, CDK19) that we have yet to explore.
What regulatory advantages do the paralogs offer the kinase module? How much
functional overlap is there between the paralogs, and what is the relative expression
between them? Does their expression change depending on cell state, and how would
their relative expression levels affect cell state? And then, there is the added dimension of
cell signaling factors that may or may not influence Mediator and its kinase module, or
vice versa.
The great web of interactions between Mediator, the kinase module, the various
transcription factors, and the multitude of signaling molecules is falling into place pieceby-piece, but work is far from finished. The benefits of this knowledge extend beyond
molecular biology, stem cell biology, and biochemistry and into the realm of clinical
application. Given a more complete map of cell state regulation, we may one day see the
efforts of this research pay off in the form of regenerative medicine involving stem cell
therapies that are tailorable to individual patients, therefore maximizing patient benefit
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and minimizing patient harm. We may discover ways to manipulate stem cells that we
previously could have only imagined, and then we’ll have uncovered the elusive fountain
of youth. These possibilities are beyond our grasp now, but no great height was ever
reached without a solid foundation, and it is this foundation that current research must
continue to build.
Ultimately, the study of Mediator and its kinase module will necessitate increased
collaboration between the fields of stem cell biology, cell signaling, and transcriptomics.
That level of research is a difficult undertaking given the shear complexity of gene
expression regulation. One of the joys of biology is that despite how complex it all may
seem, there is a hidden elegance to all the intertwined systems that make cells and
organisms function, and function well. Unfortunately, the nature of foundational research
tends to render an individual researcher unable to see the forest for the trees, but as
scientists, we have the pleasure of knowing that the forest is there, waiting to be fully
explored.

CHAPTER 2
THE ROLE OF MED31 IN ADIPOGENESIS
This work was previously published in Molecular Biology Reports, titled “MED31
involved in regulating self-renewal and adipogenesis of human mesenchymal stem cells.”
Permission to reuse this work in this dissertation is granted by Springer Nature under
their Author Reuse Policy. Full citation: Beadle, E. P., Straub, J. A., Bunnell, B. A. &
Newman, J. J. MED31 involved in regulating self-renewal and adipogenesis of human
mesenchymal stem cells. Mol. Biol. Rep. 45, 1545–1550 (2018).
2.1

Background

Mesenchymal stem cells (MSCs) are multipotent, adult stem cells derived from
both adipose tissue (ASCs) and bone mar- row (bMSCs)139. MSCs retain the capacity to
be naturally differentiated into osteoblasts, adipocytes, chondrocytes, stromal cells, and
myoblasts. This differentiation capacity allows for many potential cellular therapies to
repair damage in bones, tendons, and muscles. MSCs also have immunomodulatory
properties that allow them to seek out sites of inflammation in the body and, upon arrival
to their destination, secrete regulatory cytokine and chemokine factors to suppress
inflammation which has been shown to delay graft rejection and treat some autoimmune
disease5,140,141.
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The Mediator complex is a transcriptional coactivator with the capacity to loop
double stranded DNA and coordinate transcriptional activation and repression in a celltype specific manner. During the looping process, enhancer elements and their bound
transcription factors are folded closer to the promoter region of the gene. As the DNA is
looped by Mediator, an elaborate network of protein–protein interactions is formed
between general transcription factors, RNA Polymerase II, Mediator, and cell type
specific transcription factors bound at enhancer elements. Weighing approximately 1.5
megadaltons, Mediator is a multi-module complex that is comprised of approximately 30
subunits organized into four different sub-modules and is conserved across the eukaryotic
domain from yeast to humans142.
Individual Mediator subunits can form protein–protein interactions with different
key regulators of cell state, showing the importance for Mediator in the proper regulation
of cell state and development. For example, loss of MED1 and MED12 in mouse
embryonic stem cells causes spontaneous differentiation suggesting a regulatory role for
MED1 and MED12 in the pluripotency of ESCs14. MED1 and MED12 have been shown
to be required for proper hematopoietic stem cell population maintenance143 and proper
cardiac development144, and MED12 is essential for neuronal development in many
different organisms including zebrafish114, mice40, and even humans117–119,145,146.
MED31 is one of the most conserved subunits of the Mediator complex; however,
it is also one of the least characterized with regards to its biological function in
multicellular organisms. MED31 is an integral part of the Mediator complex displaying a
variety of functions in several model organisms and cell lines. MED31 has recently been
identified as a binding target for TREX-2, a protein involved in both transcription and the
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export of mRNA out of the nucleus through the nuclear pore complex. In the absence of
MED31, TREX-2 is unable to bind to Mediator thereby inhibiting the formation of the
pre-elongation complex for mRNA synthesis and RNA Pol II phosphorylation147.
MED31 acts as a protein bridge within the Mediator complex connecting both the head
and middle modules, and when labelled or deleted its structural interactions can be
disrupted. This structural disruption ultimately results in abolished protein interactions
thus modifying transcription in a very specific manner9.
MED31’s role in mammalian development was first characterized in 2010 when
Risley et al. identified a mouse MED31 mutant that displayed late gestation lethality and
significant growth defects such as decreased cell proliferation in mouse embryonic
fibroblasts (MEFs) and limb buds, smaller bone structures, and decreased expression of
the essential developmental genes Sox9, Col2A1, mTOR, and cyclin B148. In 2013,
Schiano et al. found that MED31, along with MED1 and MED20, were significantly
upregulated in three osteosarcoma cell lines compared to osteoblasts149. In addition, Jiang
et al. in 2014 found that MED1 and MED31 were consistently overexpressed in
osteosarcoma and that inhibition of either reduced both cell proliferation and cell cycle
progression. Further investigation during this study suggested that MET signaling and
ERK 1/2 phosphorylation were reduced, possibly explaining this phenotype. Taken
together, these results suggest that MED31 plays a role in cell proliferation and cell cycle
progression in osteosarcoma cells possibly through MET signaling or the ERK 1/2
signaling cascade150. The role of MED31 in normal cell state maintenance and directed
differentiation remains uncertain. Given existing evidence for a role of MED31 in
osteogenesis, we were interested in looking at adipogenesis, a process often considered
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opposing to osteogenesis. Here we show that the loss of MED31 is not lethal to hMSCs
but does impact the rate of proliferation and impedes adipogenesis, suggesting a critical
role for MED31 in hMSC fate.
2.2
2.2.1

Methods

Cell Culture
Human bone marrow-derived mesenchymal stem cells (hMSCs) were maintained

in MEM-α containing 16.9% fetal bovine serum, 1% Penicillin and Streptomycin, and
1% l-Glutamine. Cells were cultured in a humidified incubator at 37 °C and 5% CO2.
The 5062L donor cells were isolated from a normal, healthy donor and were
characterized and provided by Dr. Bruce Bunnell and his lab at Tulane University School
of Medicine. The cell line used had no further donor information disclosed to prevent
data biases. For in vitro adipocyte differentiation assays the cells were cultured in
AdipoQual™ Medium (LaCell: LaADM-500) for the duration of the differentiation
protocol. After reaching the terminal time point, the cells were fixed in formalin and
stained with Oil Red O. Levels of adipogenic differentiation were quantified by
extracting Oil Red O stain using isopropanol and read at 544 nm. Stain extractions were
normalized against the protein content of the samples collected using RIPA buffer and
quantified using Bradford assays. Assays were performed in biological triplicates.
Statistical analysis was performed using unpaired, two-tailed t-tests.
2.2.2

Transient Transfections and Small Interfering RNAs
HMSCs were seeded at approximately 40% confluence and transfected 24 h later

with 10 µM stock concentrations of Med31 siRNA (Thermo Fisher; 4392420) or a
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scrambled siRNA negative control (Thermo Fisher; 4390843) using Lipofectamine
RNAimax (Invitrogen) following the manufacturer’s protocol.
2.2.3

RNA Extraction, cDNA Synthesis, and qRT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen) following the

manufacturer’s protocol. For microarray analysis, total RNA was extracted using
RNeasy® Mini Kits (Qiagen) following the manufacturer’s protocol. cDNA was
synthesized using qScript™ cDNA SuperMix (Quanta Biosciences) following the
manufacturer’s protocol. Quantitative reverse transcription-PCR (qRT-PCR) was used to
quantify transcript expression levels for med31, adiponectin, and srebp-1c. qRT-PCR
was performed using PowerUp™ SYBR© green master mix as designated by the
manufacturer’s protocol on the Applied Biosystems StepOnePlus™ qRT-PCR System.
Gene expression levels were normalized to gapdh using CT values. Fold changes and
relative remaining transcript were calculated using the 2−𝛥𝛥𝐶T method. Results were
reported as an average of three or more biological replicates with error bars denoting the
standard error of the mean (SEM).
2.2.4

Western Blotting
HMSCs were seeded at 3 × 105 cells per 10 cm dish and cultured overnight. Upon

reaching terminal time point post transfection with Lipofectamine® RNAiMAX, the cells
were washed twice with PBS and harvested on ice using 400 µL RIPA lysis buffer
(Abcam) supplemented with a Pierce™ EDTA-Free Protease Inhibitor Mini Tablet
(Thermo). Whole cell lysates were agitated for 30 min at 4 °C and then centrifuged for 20
min at 12,000 RPM at 4 °C. Protein samples were quantified using BSA standard curves
generated using Bradford assays. SDS-PAGE was performed using a Mini- PROTEAN®
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TGX™ (Bio-Rad) gel and a standard protocol. Proteins were transferred onto a TransBlot® Turbo™ Transfer Pack 0.2 µm PVDF membrane (Bio-Rad) using a Trans-Blot®
Turbo™ transfer system (Bio-Rad) and the manufacturer’s protocol. After transfer,
membranes were cut into designated pieces and blocked for 2 h in 5% milk in 1× TBS
with 0.1% Tween®-20. The membrane was probed overnight with primary antibody
(1:100 for MED31; 1:3000 for GAPDH), washed 5 times, and probed with secondary
antibody (1:1000). Blots were developed using ECL and chemiluminescence. The
primary antibodies used were obtained from Santa Cruz Biotechnology (sc-101189) and
Abcam (ab9485) for MED31 and GAPDH, respectively.
2.2.5

AlamarBlue Cell Proliferation Assay
HMSCs were seeded at 4000 cells per well on 24 well tissue culture treated

plates. The hMSCs were transfected 24 h post seeding and allowed to incubate for
another 24 h following transfection. After 24 h, the alamarBlue assay was performed as
instructed by the manufacturer’s protocol. Fluorescence readings were recorded at
560/590 nm on a Cytation™ 5 plate reader (BioTek).
2.2.6

Live/dead Assay
A cell viability assay was performed using ReadyProbes® Cell Viability Imaging

Kit (Life Technologies) following the manufacturer’s protocol for untreated, negative
control, and MED31 knockdown cells. Images were taken on the EVOS FL imaging
system and analyzed using ImageJ software. The counted nuclei of both dead (red) and
live cells (blue) were averaged for six biological replicates and a t-test was used to
calculate significance.
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2.2.7

Microarray and GO Analysis
RNeasy® mini kits (Qiagen) were used to extract total RNA from hMSCs treated

with a negative control siRNA or a Med31 siRNA after 72 h post transfection. Full
transcriptome array hybridization was performed using GeneChip™ Human Genome
U133 Plus 2.0 Arrays (Affymetrix) at Louisiana Health Sciences Center-Shreveport. Data
analysis was performed using Affymetrix™ software to determine fold change of
knockdown compared to control samples. The DAVID bioinformatics database, version
6.8, was used to perform gene ontology (GO) analysis for the significantly different
genes151. The functional annotation clustering tool was used to retrieve GO terms
corresponding to the biological process, molecular function, or cellular compartment of
each differentially regulated gene. Histone clusters were differentially regulated and
created a high volume of GO terms regarding DNA condensation and transcriptional
regulation. Histone clusters were excluded for a secondary analysis to evaluate the other
differentially expressed genes as a response to MED31 knockdown.
2.2.8

Statistical Analysis
Statistical analysis was performed using a Student’s two tailed t-test when

appropriate. ANOVAs were used to establish significance for the microarray data and for
any other assays where appropriate.
2.3
2.3.1

Results

MED31 Knockdown Does Not Affect hMSC Viability
MED31 is an integral part of the Mediator complex located in the middle module

of the complex (Figure 2-1). To determine the functional role of MED31 in
mesenchymal stem cells, an siRNA-mediated transfection was used to knock down
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MED31. Knockdowns were allowed to incubate and demonstrated a significant decrease
in MED31 transcript up to 5 days (Figure 2-2) and a significant reduction in protein at 4
days or 96 h (Figure 2-3). To assess the initial effects of a MED31 knockdown on selfrenewal, alamarBlue assays and cell counting were performed on multipotent hMSCs.
The alamarBlue assay demonstrated a decrease in the proliferative rate of MSCs
suggesting some impact on cell state following MED31 knockdown (Figure 2-4). This
was complimented with a cell count experiment that demonstrated no significant
difference in cell number over time between MED31 knockdown and negative control
knockdown cells (Figure 2-5). However, a difference was observed between the negative
control and untreated cells indicating some impact of transfection on cell viability.

Figure 2-1: Mediator complex highlighting the location of the MED31 subunit in the
complex.
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Figure 2-2: med31 transcript remaining following MED31 knockdown in
undifferentiated hMSCs at 48 h, 72 h, and 5 days post-transfection. All data points
represent the average of three biological replicates and data is normalized to gapdh for
each sample. Error bars represent standard error of the mean.
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Figure 2-3: MED31 protein remaining (top) and protein quantification via ImageJ
analysis (bottom) following MED31 knockdown. Western blot represents whole cell
lysates of undifferentiated cells collected 96 h post-transfection. All data points
represent the average of three biological replicates and data is normalized to GAPDH
for each sample. Error bars represent standard error of the mean. P < 0.05.
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Figure 2-4: AlamarBlue cell assay. P < 0.05 between negative and MED31
knockdown samples, indicating slowed proliferation following loss of MED31.

*

Figure 2-5: Cell counting experiment quantifying viable cells following MED31
knockdown confirming an impact of transfection but no difference in viable cell
number between control and MED31 knockdown samples.
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2.3.2

MED31 Required for Maintenance of Self-Renewing State
To determine if the slowed proliferation might be the result of spontaneous

differentiation that could be assessed by changes in gene expression, microarray analysis
was performed. Microarray analysis further indicated a decrease in self-renewal
capabilities 72 h after knockdown of MED31 (Figure 2-6). Microarray analysis of
biological triplicate experiments demonstrated a significant (threefold) decrease in med31
transcript, validating knockdown. In addition, of the 105 genes that showed a greater than
twofold decrease in gene expression, gene ontology suggests a majority of these genes
are associated with cell replication. This includes transcripts for genes involved in
telomere organization and DNA replication. Some genes, including flg appear more than
once, indicating probes for different transcripts, while simultaneously confirming a
significant change in expression of those genes. Finally, of the 18 genes that
demonstrated a greater than twofold increase in expression, gene ontology terms
highlighted the extracellular compartment, plasma membrane, and cell–cell signaling,
while also reporting female pregnancy genes as upregulated in response to MED31
knockdown.

Figure 2-6: Heat map represents genes of greatest fold change resulting from MED31
knockdown determined by microarray analysis. Asterisks indicate genes of interest
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with * representing genes involved in cell cycle and self-renewal and ** representing
genes involved in development and differentiation.
2.3.3

MED31 Regulates Adipocyte Differentiation
HMSCs have the ability to differentiate down the mesodermal lineage and are

easily differentiated in the lab into adipocytes and osteoblasts. Here, adipocyte
differentiation was induced for 7 days following an siRNA-mediated MED31
knockdown. A single transfection was performed 24 h before initiating differentiation.
Transcript and protein levels confirm a significant knockdown up to 7 days post
transfection (Figure 2-7; Figure 2-8) providing support for the observed phenotype.
Morphology, along with Oil Red O staining (Figure 2-9), demonstrate a visible decrease
in adipocyte differentiation following the loss of MED31. Finally, qRT-PCR of genes
indicative of adipocyte differentiation, srebp-1c and adiponectin, demonstrate a
significant decrease in transcript levels for each of these genes 7 days into differentiation,
further confirming the phenotypic results (Figure 2-10). This observed decrease in
adipocyte differentiation following the loss of MED31 suggests that MED31 has a role in
regulating adipogenesis by potentially activating genes responsible for adipocyte
differentiation of hMSCs. Proper moderation and regulation of differentiation is critical
for healthy development and MED31 appears to be an important feature of
developmental control (Figure 2-11).
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Figure 2-7: med31 transcript remaining following MED31 knockdown in adipogenicdifferentiated hMSCs at 7 days post-transfection. All data points represent the average
of three biological replicates and data is normalized to gapdh for each sample. Error
bars represent standard error of the mean.

52

Figure 2-8: MED31 protein remaining (top) and protein quantification via ImageJ
analysis (bottom) following MED31 knockdown. Western blot represents whole cell
lysates of adipogenic-differentiated cells collected 7 days post-transfection. All data
points represent the average of three biological replicates and data is normalized to
GAPDH for each sample. Error bars represent standard error of the mean.
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Figure 2-9: Phase contrast (top) and color micrographs (middle) of adipogenicdifferentiated hMSCs at 7 days post-transfection. Staining of lipid droplets was
performed using Oil Red O. Lipid vesicles are indicated with arrows. Oil Red O stain
extraction (bottom). All data points represent the average of three biological
replicates. Error bars represent standard error of the mean.
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*

*

Figure 2-10: qRT-PCR of early fat marker srebp-1c (top; P = 0.0016) and
adiponectin (bottom; P = 0.0306). All data points represent the average of three
biological replicates and data is normalized to gapdh for each sample. Error bars
represent standard error of the mean. P < 0.05 between knockdown and control for
both genes.
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Figure 2-11: Loss of MED31 disrupts the balance between self-renewal and
differentiation in hMSCs.

2.4
2.4.1

Conclusion

MED31 Critical to Balance and Proper Differentiation of MSCs
Transcriptional control requires a delicate balance between gene activation and

gene silencing. This balance is especially critical in a self-renewing population of cells
that has the potential to differentiate down multiple lineages. If misregulated, cells will
improperly differentiate or proliferate, leading to developmental defects or cancer. Here
we report the role of MED31 in the maintenance and regulation of mesenchymal stem
cell state. Reduction of MED31 by siRNA-mediated knockdown demonstrates a role for
MED31 in maintaining the metabolism and proper differentiation of MSCs. MED31
appears to be critical for differentiation of hMSCs suggesting an important role for the
subunit in transcriptional activation.
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CHAPTER 3
MED12 AND ADIPOGENESIS

3.1

Background

Eukaryotic gene expression is a delicate balancing act that steers a stem cell either
toward self-renewal or differentiation down any number of possible lineages. The central
regulator of this process is the Mediator of RNA polymerase II (RNAP II), also known as
the Mediator complex. This highly-conserved complex is composed of 30 subunits in
humans3 and, together with cohesin, forms a protein bridge that links transcription factors
found at linearly-distant DNA elements to cell type-specific gene promotors. After
forming a chromatin loop between enhancer-associated gene regulatory elements and the
pre-initiation complex14, Mediator recruits RNAP II to begin gene transcription.
Mediator’s subunits are divided among four distinct modules: the head, middle,
tail, and kinase9. The head and middle modules interact with RNAP II and the preinitiation complex while the tail module interacts with enhancer-bound transcription
factors2. Taken together, these three modules form what is termed “core Mediator.” The
four-subunit kinase module, however, can dissociate itself from the core8,37. Although the
mechanism that triggers the kinase module’s dissociation from the rest of Mediator is not
entirely understood, it appears to have a context-dependent role in regulating core
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Mediator’s activity: activating Mediator in some circumstances54 and repressing it in
others30,51,152.
The Mediator kinase module is composed of four subunits, three of which have
mutually-exclusive paralogs: MED12/L, MED13/L, CDK8/19, and Cyclin C. Of these,
MED12 stands out as a particularly active subunit. MED12 has been associated with
many cancers86,87, and several MED12 mutations have been implicated in phyllodes
tumors of the breast102,103,106,107,153,154, uterine leiomyomas68,89,99–101,155,91–98, and prostate
cancer108–110. MED12 is also a factor in FG (Oppitz-Kaveggia) syndrome117, Lujan
syndrome118, and Ohdo syndrome119; each of which is X-linked (MED12 is located at
Xq13.1) and is associated with intellectual disability. The breadth of different diseases
tied to MED12 may be due to the subunit’s responsibility in activating CDK8/19’s kinase
activity64.
To date, MED12 has been found to associate with super-enhancers, interact with
NANOG, SOX2111, and PRC1 in pluripotent stem cells112, interact with Wnt/β-Catenin in
core Mediator recruitment to cell type-specific genes49, maintain HSC viability26, and
interact with SOX10 in glial cells40. This all suggests that MED12 is an indispensable
component of stem cell state regulation. In this paper, we explore a new potential
interaction between MED12 and PPARG in human adult adipose-derived stem cells
(ASCs) undergoing adipogenesis. PPARG is the central regulator of adipogenesis, and
this finding, in addition to being novel, is important for the field of clinical medicine. The
discovery of new interactions between gene expression regulators like the Mediator
subunit MED12 and other transcription factors advances our understanding of
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multipotent stem cell regulation, moving us closer to the application of adult stem cells as
a safe and effective tool of regenerative medicine.
3.2
3.2.1

Methods

Cell Culture
Human adipose-derived mesenchymal stem cells (hASCs) were maintained in

MEM-α containing 16.9% fetal bovine serum, 1% Penicillin and Streptomycin, and 1% lGlutamine. Cells were cultured in a humidified incubator at 37 °C and 5% CO2. The 412
donor cells were isolated from a normal, healthy donor and were characterized and
provided by Dr. Bruce Bunnell and his lab at Tulane University School of Medicine. The
cell line used had no further donor information disclosed to prevent data biases. For in
vitro adipocyte differentiation assays the cells were cultured in AdipoQual™ Medium
(LaCell: LaADM-500) for the duration of the differentiation protocol. After reaching the
terminal time point, the cells were fixed in formalin and stained with Oil Red O. Levels
of adipogenic differentiation were quantified by extracting Oil Red O stain using
isopropanol and read at 544 nm. Stain extractions were normalized against the protein
content of the samples collected using RIPA buffer and quantified using Bradford assays.
Assays were performed in biological triplicates. Statistical analysis was performed using
unpaired, two-tailed t-tests.
3.2.2

Transient Transfections and Small Interfering RNAs
Human ASCs were seeded at approximately 40% confluence and transfected 24 h

later with 10 µM stock concentrations of Med31 siRNA (Thermo Fisher; 4392420) or a
scrambled siRNA negative control (Thermo Fisher; 4390843) using Lipofectamine
RNAimax (Invitrogen) following the manufacturer’s protocol.
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3.2.3

RNA Extraction, cDNA Synthesis, and qRT-PCR
Total RNA was extracted using TRIZOL reagent (Invitrogen) following the

manufacturer’s protocol. For microarray analysis, total RNA was extracted using
RNeasy® Mini Kits (Qiagen) following the manufacturer’s protocol. cDNA was
synthesized using qScript™ cDNA SuperMix (Quanta Biosciences) following the
manufacturer’s protocol. Quantitative reverse transcription-PCR (qRT-PCR) was used to
quantify transcript expression levels for med12 and pparg. qRT-PCR was performed
using PowerUp™ SYBR© green master mix as designated by the manufacturer’s
protocol on the Applied Biosystems StepOnePlus™ qRT-PCR System. Gene expression
levels were normalized to gapdh using CT values. Fold changes and relative remaining
transcript were calculated using the 2−𝛥𝛥𝐶T method. Results were reported as an average
of three or more biological replicates with error bars denoting the standard error of the
mean (SEM).
3.2.4

Western Blotting
Human ASCs were seeded at 3 × 105 cells per 10 cm dish and cultured overnight.

Upon reaching terminal time point post transfection with Lipofectamine® RNAiMAX,
the cells were washed twice with PBS and harvested on ice using 400 µL RIPA lysis
buffer (Abcam) supplemented with Halt™ Protease & Phosphatase Inhibitor Single-Use
Cocktail (Thermo). Whole cell lysates were agitated for 30 min at 4 °C and then
centrifuged for 20 min at 12,000 RPM at 4 °C. Protein samples were quantified using
BSA standard curves generated using Bradford assays. SDS-PAGE was performed using
a Mini-PROTEAN® TGX™ 4-15% gel (Bio-Rad) and a standard protocol. Proteins were
transferred onto a PVDF membrane at 100 V for 1 hr according to a standard protocol.
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After transfer, membranes were cut into designated pieces and blocked for 2 h in 5% milk
in 1× TBS with 0.1% Tween®-20. The membrane was probed overnight with primary
antibody (1:1000 MED12; 1:500 PPARG; 1:3000 GAPDH; 1:1000 TUBA1A), washed 5
times, and probed with secondary antibody (1:1000). Blots were developed using ECL
and chemiluminescence. The primary antibodies used: MED12 (Bethyl; A300-774A);
PPARG (Cell Signaling; 81B8); GAPDH (Abcam; ab9485); TUBA1A (Abcam; ab4074).
3.2.5

AlamarBlue Cell Proliferation Assay
Human ASCs were seeded at 4000 cells per well on 24 well tissue culture treated

plates. The hASCs were transfected 24 h post seeding and allowed to incubate for another
72 h following transfection. After 72 h, the alamarBlue assay was performed as instructed
by the manufacturer’s protocol. Fluorescence readings were recorded at 560/590 nm on a
Cytation™ 5 plate reader (BioTek).
3.2.6

Live/dead Assay
A cell viability assay was performed using ReadyProbes® Cell Viability Imaging

Kit (Life Technologies) following the manufacturer’s protocol for untreated, negative
control, and MED31 knockdown cells. Images were taken on the EVOS FL imaging
system and analyzed using ImageJ software. The counted nuclei of both dead (red) and
live cells (blue) were averaged for six biological replicates and a t-test was used to
calculate significance.
3.2.7

Immunofluorescence Staining
HASCs were seeded at 4000 cells per well on a 24 well tissue culture treated

plate. The hASCs were transfected 24 h later and incubated for another 72 h. After 72 h,
the Alexa Fluor® 555 Phalloidin (Life Technologies, A34055) and DAPI (Thermo Fisher
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Scientific, 62248) staining was performed using the manufacturer’s protocol. Phalloidin
was diluted to 1:40 and DAPI to 1:2000. Plate was imaged using a Cytation™ 5 plate
reader (BioTek).
3.2.8

Statistical Analysis
Statistical analysis was performed using a Student’s two tailed t-test when

appropriate. All error bars represent standard error of the mean.
3.3
3.3.1

Results

Kinase Subunit Expression Fluctuates During hASC Adipogenesis
Differentiation is a well-orchestrated process that relies on the convergence of

environmental factors, cell signaling, transcription factors, and gene expression
regulation to produce a nearly irreversible alteration of a stem cell’s gene expression
profile, leading to an overall change in the stem cell’s cellular identity. Adipogenesis, is
the process of a multipotent stem cell differentiating into a mature adipocyte capable of
accumulating and storing fatty acids within lipid vesicles. In order to establish a baseline
for hASC adipogenesis, cells were characterized across four timepoints: day 0, 7, 14, and
21 days following the induction of adipogenesis (Figure 3-1). Lipid vesicles, begin to
emerge by day 7 as evidenced by phase-contrast imagine and Oil Red O staining. There is
little difference in lipid vesicle expression between day 14 and day 21 of adipogenesis.
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Figure 3-1: Phase contrast microscopy and Oil Red O staining of untreated hASCs at
0-, 7-, 14-, and 21-days post-induction with adipogenic media. Images were captured
at 10x magnification.
Mediator is understood to play a critical role in cell type-specific gene expression,
and this role includes regulating activity on the part of the kinase module. In order to
establish the Mediator kinase module subunits as participants in regulating
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differentiation, we first sought to establish baseline expression of the four kinase module
subunits (MED12, MED13, CDK8 and CCNC) over the course of adipogenesis prior to
and 7, 14, and 21 days after inducing adipogenesis (Figure 3-2, Figure 3-3, Figure 3-4,
Figure 3-5, and Figure 3-6). MED12, MED13, and CDK8 are highly expressed prior to
inducing adipogenic differentiation, indicating probable involvement in the transition
from multipotency to a differentiation program. MED12 and CDK8 then decrease in
expression and reach a low point by day 14 before being upregulated again at day 21.
These data suggest that MED12 and CDK8, rather than MED13, are required not only in
the initiation of adipogenesis but perhaps also in the maintenance of mature adipocytes.
These subunits may play less of a role in the differentiation process as well given their
reduced expression over the course of adipogenesis.
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Figure 3-2: Western blots showing protein expression of kinase module subunits
MED12, CDK8, and MED13 in untreated hASCs at day 0-, 7-, 14-, and 21-days postinduction with adipogenic media.
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Figure 3-3: Quantitative RT-PCR of med12 in untreated hASCs at day 0-, 7-, 14-, and
21-days post-induction with adipogenic media. The experiments were performed in
biological and technical triplicates and the data were normalized to gapdh expression
at their respective timepoints.
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Figure 3-4: Quantitative RT-PCR of med13 in untreated hASCs at 0-, 7-, 14-, and 21days post-induction with adipogenic media. The experiments were performed in
biological and technical triplicates and the data were normalized to gapdh expression
at their respective timepoints.

67

7

CDK8 fold change

6
5
4
3
2
1
0
Day 0

Day 7

Day 14

Day 21

Figure 3-5: Quantitative RT-PCR of cdk8 in untreated hASCs at 0-, 7-, 14-, and 21days post-induction with adipogenic media. The experiments were performed in
biological and technical triplicates and the data were normalized to gapdh expression
at their respective timepoints.
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Figure 3-6: Quantitative RT-PCR of ccnc in untreated hASCs at 0-, 7-, 14-, and 21days post-induction with adipogenic media. The experiments were performed in
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biological and technical triplicates and the data were normalized to gapdh expression
at their respective timepoints.

3.3.2

MED12 Knockdown Does Not Affect hASC Self-Renewal
In order to test our assumptions that MED12 is involved not only in initiating

adipogenesis but in adipocyte maintenance, we performed transient siRNA transfections
to knock down MED12 expression in hASCs. Our MED12-siRNA transfections were
effective at reducing med12 mRNA by nearly 80% (Figure 3-7) with an accompanying
decrease in MED12 protein expression (Figure 3-8). AlamarBlue analysis revealed
neglible change in hASC metabolism as a result of the knockdown (Figure 3-9).
Additionally, cell viability (Figure 3-10) and morphology (Figure 3-11) appeared to be
unchanged as a result of the knockdown. These results suggest that neither the transient
transfection nor the decreased expression of MED12 significantly impacts hASC selfrenewal and viability.
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Figure 3-7: RNA-level validation of siRNA-mediated MED12 knockdown via qRTPCR 72 hours post-transfection. The experiments were performed in biological and
technical triplicates and the data were normalized to gapdh. P = 0.0019.
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Figure 3-8: Protein-level validation of siRNA-mediated MED12 knockdown via
western blot 72 hours post-transfection (top). Quantitative analysis was performed
using ImageJ (bottom). Data were normalized to GAPDH. Only single datapoints
were obtained for this data.
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Figure 3-9: AlamarBlue assay performed 72 hours post-knockdown. Metabolic
activity is not significantly reduced in hASCs in the MED12 knockdown. Experiment
was performed in biological triplicates. P > 0.05 for each timepoint.

Figure 3-10: Live-dead staining of hASCs 72 hours post-knockdown. Cell viability is
not significantly affected by the MED12 knockdown.
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Figure 3-11: DAPI and phalloidin staining of hASCs 72 hours post-knockdown.
Images were captured at 10x magnification. Cellular morphology is not significantly
impacted by MED12 knockdown.
3.3.3

MED12 Knockdown Leads to Decreased Adipogenesis of hASCs
Given the efficacy of our transfection system and its low impact on hASC

viability and proliferation, we then characterized hASCs undergoing adipogenesis during
MED12 knockdown. First, we performed microscopy and Oil Red O at the 7-day and 14day timepoints following MED12 knockdown and induction of adipogenesis.
Adipogenesis at the 7- and 14-day timepoints is clearly reduced following the knockdown
of MED12 (Figure 3-12). The efficacy of our knockdowns in these adipogenesis assays
were similar to that observed in the self-renewal assays (Figure 3-13). After validating
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the MED12 knockdown over time, we characterized the protein expression of the central
regulator of adipogenesis, PPARG, and found that its expression was downregulated in
the MED12 knockdown (Figure 3-14, Figure 3-15). These data confirm a role for
MED12 in initiating adipogenesis, but further experimentation was required to explore
the question of MED12’s declining role during adipogenesis and its increasing
importance for adipocyte maintenance.

Figure 3-12: Phase contrast and Oil Red O staining of hASCs undergoing
adipogenesis at 7- and 14-days post-induction. Magnification 10x.
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Figure 3-13: Protein-level validation of siRNA-mediated MED12 knockdown via
western blot (top). ImageJ analysis of MED12 knockdown 14 days postdifferentiation (bottom). Data were normalized to GAPDH. Experiment was
performed in biological triplicates. P = 0.0011.
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Figure 3-14: Western blot of PPARG 3-, 7-, and 14-days post-induction. PPARG
expression appears to be reduced in the MED12 knockdown.

140

PPARG Fold change

120
100
80

3D
7D

60

14D
40
20
0
Scrambled siRNA

MED12 siRNA

Figure 3-15: ImageJ analysis of PPARG at 3-, 7-, and 14-days post-induction.
PPARG expression appears to be reduced in the MED12 knockdown. 3- and 7-day
timepoints were normalized to TUBA1A. 14-day timepoint was normalized to
GAPDH. 3D p = 0.038. 7D p = 0.037. 14D p = 0.045.
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3.3.4

MED12 Plays a Role During Early Adipogenesis
We next sought to explore MED12’s changing role in adipogenesis over time. A

set of experiments were devised that would delay MED12 siRNA transfection to 3 days
(3d) and 7 days (7d) after induction of adipogenesis in addition to a standard 24-hour preinduction (PD) group as a control (Figure 3-16). Each group was collected at 14-days
post-induction and characterized via Oil Red O staining and qRT-PCR. After validating
the MED12 knockdowns via endpoint PCR (Figure 3-17), we performed Oil Red O
staining (Figure 3-18) and stain extraction (Figure 3-19). Lipid vesicle staining appears
to be reduced in the PD and 3d groups compared to a scrambled siRNA control, but the
7d group revealed an insignificant change on lipid vesicle staining compared to the
scrambled siRNA control. This evidence suggests that by day 7 of adipogenesis, there is
less of a requirement for MED12 in directing gene expression driving hASC
differentiation. The expression of pparg was then compared at each timepoint (Figure
3-20). Each differentiation timepoint saw a significant decrease in pparg mRNA
expression compared to the scrambled siRNA control except for the 7d group which saw
its expression mostly unchanged compared to the control. This marked shift in pparg
expression upon MED12 knockdown 7-days post-induction, taken together with the
microscopy and stain extraction data, does not rule out a potential role for MED12 in
maintaining adipogenesis and may even point toward an interesting relationship between
MED12 and PPARG. The sharp increase in pparg expression and the similar lipid vesicle
staining in the 7d group suggest the existence of a compensatory mechanism for PPARG
in adipocyte maintenance in a MED12-depleted state.
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Figure 3-16: Experimental design of the delayed MED12 knockdown assay.

Figure 3-17: Endpoint RT-PCR of gapdh and med12 for the pre-induction (PD), 3days post-induction (3d), and 7-days post-induction (7d) MED12 knockdown.
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Figure 3-18: Phase-contrast microscopy (left) and Oil Red O staining (right) for the
pre-induction MED12 knockdown and two post-induction MED12 knockdown
groups. Magnification 4x.
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Figure 3-19: Stain extraction performed for the pre-induction (PD), 3-days postinduction (3d), and 7-days post-induction (7d) MED12 knockdown. PD p = 6.08E-05.
3D p = 8.78E-05. 7D p = 0.66.

80
1.4

MED12 Fold change

1.2
1
0.8

PD
3D

0.6

7D
0.4
0.2
0
NC

KD

1.8
1.6

PPARG Fold change

1.4
1.2
1

PD

0.8

3D
7D

0.6
0.4
0.2
0
NC

KD

Figure 3-20: Quantitative RT-PCR validation of med12 knockdown (top) and
characterization of pparg expression (bottom) for the pre-induction (PD), 3-days postinduction (3D), and 7-days post-induction (7D) MED12 knockdown. Data were
normalized to gapdh. Med12 p < 0.05. Pparg p > 0.05.

3.4

Conclusion

The Mediator complex is an indispensable part of cell type-specific gene
regulation in hASCs, and its regulation guides individual cells toward either self-renewal
or differentiation. The kinase module plays a prominent role in gene expression, and our
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results point to MED12 involvement beyond the point of cell fate determination and into
the maintenance of differentiated adipocytes. Though these data alone are not sufficient
to link MED12 and PPARG via protein-protein interactions, it has illuminated the
possibility that these two critical regulators act in concert during the course of
adipogenesis even into the later stages of differentiation.
3.5

Acknowledgements

Funding for this work was provided by mini-grants awarded by the College of
Applied and Natural Sciences at Louisiana Tech University. Funding was also supported
from grants awarded by Sigma Xi to Caroline Rinderle and Onyekachi Idigo. I would like
to thank Sree Venigalla, Caroline Rinderle, and Onyekachi Idigo for their work in the lab
including cell culture, PCR, western blotting, and data analysis as well as for ideas and
writing. Each of them has contributed greatly to this work.

CHAPTER 4
CONCLUSIONS AND FUTURE WORK

4.1

Conclusions

The study of Mediator is critical for regulating gene expression, the process
through which stem cell self-renewal and differentiation is governed. Therefore,
understanding Mediator is a requirement for elucidating stem cell behavior. Work in this
area is accelerating, particularly the study of Mediator’s kinase module, which possesses
subunits responsible for many well-documented cancers and diseases, but the kinase
module’s role remains poorly defined.
Before committing fully to researching the kinase module subunit MED12,
previous work on Mediator’s smallest subunit, MED31 (Figure 2-1), was completed. In
order to establish a role for MED31 in human adult-derived stem cells, we performed
siRNA-mediated knockdowns and validated efficiency for depleting MED31 transcript
(Figure 2-2) and reducing protein expression (Figure 2-3) while characterizing its effects
on stem cell viability (Figure 2-4 and Figure 2-5). After proving the knockdown
system’s efficacy, the genome-wide effects of the MED31 knockdown were
characterized using microarray analysis, finding that the majority of genes affected by the
knockdown involved cell cycle and self-renewal (Figure 2-6). The knockdown was
further characterized through cell culture, revealing a decrease in lipid vesicle formation
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(Figure 2-9) and adipogenesis marker expression (Figure 2-10) in the MED31
knockdown group. These results showed that MED31 disrupts the delicate balance
between self-renewal and differentiation in mesenchymal stem cells (Figure 2-11). Such
results are likely due to a change in Mediator’s structural conformation brought about by
a reduction in available MED31 protein considering that MED31 is a middle module
subunit.
Following the report of observations made about MED31 in mesenchymal stem
cells, we pursued the far larger MED12 subunit implicated in many female cancers,
developmental diseases, and regulation of hematopoietic stem cells. With interest
surrounding the kinase module growing, we first sought to characterize adipogenesis
across four timepoints in adipose-derived stem cells (Figure 3-1) and kinase module
subunit expression at both the protein (Figure 3-2) and mRNA level for MED12 (Figure
3-3), MED13 (Figure 3-4), CDK8 (Figure 3-5), and CCNC (Figure 3-6). Expression of
each of the subunits across 21 days of adipogenic differentiation revealed an interesting
trend. The level of expression of all four subunits increased over time, reaching the
highest levels at the final day 21 timepoint. MED12 and MED13 fluctuated wildly
between the different timepoints, prompting further investigation into MED12’s effects
on adipogenesis. MED12 levels were diminished using an siRNA-mediated knockdown
and validated at both the mRNA (Figure 3-7) and protein levels (Figure 3-8). The
knockdown did not adversely affect stem cell metabolism (Figure 3-9), viability (Figure
3-10), or morphology (Figure 3-11). However, the MED12 knockdown did reduce lipid
vesicle formation (Figure 3-12) and PPARG expression (Figure 3-14 and Figure 3-15),
revealing the importance of MED12 in regulating adipogenesis. Pre-induction
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knockdowns cannot fully address the role of MED12 in adipogenesis over time, as we
had earlier observed MED12’s expression changes during the course of differentiation.
Therefore, we performed delayed knockdown assays (Figure 3-16) that allowed for
determining MED12’s changing role during adipogenesis from differentiation initiation
to adipocyte maintenance. Starting MED12 knockdown 7 days after inducing
adipogenesis resulted in lipid vesicle formation that was similar between the knockdown
and control cells (Figure 3-19). Initially, this suggested that MED12’s influence ends
early in adipogenesis, but this data combined with such a high level of PPARG
expression after the day 7 post-induction MED12 knockdown (which has the potential to
exceed control levels of expression) (Figure 3-20) points to a relationship between
MED12 and PPARG that may function mechanistically as a relay between the two, with
MED12 passing the baton to PPARG in later stages of adipogenesis after initiation is
complete. There is also the possibility for PPARG or other proteins working to
compensate for the decrease in MED12 expression following the knockdown.
This line of research is greatly aided by the tools and techniques of
bioinformatics. Next generation sequencing is changing the way that molecular biologists
approach the study of gene expression. As technology improves, so too do genome
databases that molecular biologists rely on for designing primers and performing gene
ontologies. Such techniques could have greatly aided research in Mediator, but the
opportunity to learn bioinformatics arrived late during the degree program and covered
the most foundational bioinformatics knowledge. However, that does not discount the
knowledge gained as invaluable.
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The sum of the work presented in this dissertation, at the very least, paves the way
for more in-depth research to be performed. Currently, there is a lack of foundational
research that focuses on the Mediator complex subunits and how they affect the selfrenewal and differentiation of clinically-relevant, human adult-derived stem cells. With
Mediator as the central regulator of eukaryotic gene transcription, it deserves more
attention in the study of cell state regulation, and this work adds to what is currently
known with regard to our MED31 and MED12 studies. Little is understood about how
the kinase module affects Mediator, let alone human adult-derived stem cells, so our
findings in this area will attract the curiosity of other scientists willing to uncover the
structure and function of this complex in development. The ultimate goal of stem cell
research should be to deploy safe and effective stem cell therapies that are autologous,
targeted, and tightly-controlled. Such therapies have the potential to be utilized for tissue
regeneration, cancer mitigation, and even general life extension. This research is an
important stepping stone toward that goal as Mediator is the key to unlocking the
potential of stem cells for use in medicine.

4.2

Future Work

Keeping with our current focus on Mediator’s kinase module, what we have
gathered from our research is that not only does MED12 affect adipogenesis in hASCs,
but there is potential for interaction with the adipogenesis regulator PPARG. In order to
determine if such an interaction exists, we must perform co-immunoprecipitation (co-IP
assays). A series of co-IP assays would be conducted during self-renewal and during
adipogenesis that could reveal a MED12-PPARG interaction. We would expect to see an
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interaction between MED12 and PPARG during adipogenesis since both are important
for regulating that process. Seeing such an interaction would confirm a role for MED12
as a coactivator of adipogenesis.
Next, PPARG expression has been the primary focus of our MED12 knockdown
characterization. Though central to adipogenesis, PPARG is only one piece of the
transcriptomic puzzle that is under the potential influence of a MED12 knockdown. A
broader survey of all genes affected in differentiating hASCs can be accomplished
through the use of RNA sequencing (RNA-seq). Such data would reveal the totality of
MED12’s influence over gene expression, and that data combined with gene ontology
would show which cellular processes are affected by MED12 during the course of either
self-renewal or adipogenesis. RNA-seq data would present the most complete picture of
how MED12 helps to direct stem cell fate.
Further still is the question of MED12 as a coactivator of transcription. If MED12
functions as a true coactivator on its own or with the kinase module, or even attached to
the core Mediator complex, the best method for discovering such a role would be to use
chromatin immunoprecipitation sequencing (ChIP-seq). ChIP-seq data analysis would
highlight MED12 binding sites on chromatin throughout the genome, including
promotors, super-enhancers, and any other locations. These discoveries could be
enhanced with chromatin conformation capture (3C) in order to map chromatin looping
which would reveal novel interactions between super-enhancers and key gene promotors
in adipogenesis. RNA-seq, ChIP-seq, and 3C are great undertakings, representing a large
risk with the potential for a large reward.
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An outstanding question with regard to the Mediator kinase module is the role of
the kinase module paralogs. Very little research exists regarding the paralogs and why
they are necessary. As is true for most things in biology, if the kinase module paralogs
were not necessary, they would not exist. This area of Mediator study is a frontier that
needs to be explored, and exploring it will require rounds of knockdown assays to
understand the function of each paralog and characterizations of the expression of each
paralog in turn to look for any compensatory mechanisms at work. Such research should
be combined with self-renewal and differentiation assays to further the understanding of
the roles these unique subunits play in maintaining stem cell state. This work could be
conducted with less investment of resources with a disproportionately higher payoff in
advancing the field of Mediator research.
Our future work represents a roadmap that, if pursued, would present a nearly
exhaustive set of data for MED12’s involvement in cell state regulation in hASCs and
would inevitably lead to further questions. Of course, this research seeks to clarify the
piece of the stem cell regulation puzzle that represents MED12 and the Mediator kinase
module. Overall, our current research and our proposed future work would contribute
greatly to the body of knowledge of stem cell biology and how hASCs are regulated by
the critical Mediator complex, pushing the field ever closer toward safe and efficacious
applications for stem cells in medicine and biomedical engineering.

APPENDIX A
BIOINFORMATICS
This work was performed through an internship program at the National Center
for Genome Resources in Santa Fe, New Mexico during the summer of 2018.
A.1

Introduction

Well before James Watson and Francis Crick’s revolutionary paper on the
structure of the DNA double helix, biologists realized that biological organisms, and even
entire species, rely on basic sequence information for survival. Since the cementing of the
central dogma of molecular biology that states that biological sequence information
largely flows from DNA to RNA to protein, scientists have sought to fully understand the
nature of these information sequences both in what constitutes them and how they are
utilized by molecular machinery to sustain cells and organisms. Today, we live in a postHuman Genome Project world. Computers, which now dominate every aspect of life in
developed countries, have propelled a once emerging interdisciplinary field, termed
“bioinformatics,” to the forefront of the ever-accelerating march of biological
understanding, pushing the boundaries of what we know about biological systems farther
into the frontier.
Bioinformatics concerns itself with both the content and expression of biological
information, allowing for the mapping of entire genomes, discovery of genetic causes for
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disease, illumination of genetic pathways and the transcriptome, and the understanding of
both evolution and ecology. The field of bioinformatics relies not only on biologists, but
also on statisticians, mathematicians, and computer scientists. Bioinformatics exists not
within the realms of in vivo, in vitro, or in situ study, but within the realm of in silico:
scientific advancement within silicon semiconductors156.
The foundation for what would decades later become the field of bioinformatics
began with the work of Frederick Sanger who is the fourth person in history to have ever
achieved the honor of receiving the Nobel Prize twice—both of which happen to be in
Chemistry. The first was awarded in 1958 for decoding the amino acid sequence of
bovine insulin. The second, awarded in 1980, recognized his achievement in developing a
procedure for the determination of nucleic acid sequences in DNA. Termed “Sanger
sequencing,” this method involves the use of dideoxynucleosidetriphosphate chain
terminators labeled with either fluorescent or radioactive dyes157.
Though rudimentary by today’s standards, Sanger sequencing was the gateway
technology that made the Human Genome Project possible. The National Institutes of
Health, together with the United States Department of Energy, established the National
Center for Human Genome Research initially led by none other than James Watson in
1988. Slated to be a fifteen-year program, the Project’s objective revolved around
mapping the entire human genome including establishing the full nucleotide sequence
and the locations of all genes; however, the Project’s goals were actually two-fold. The
second objective was to pioneer new developments in sequencing technology as the
Project proceeded158. Necessity is the mother of invention, and the Human Genome
Project created the necessity for modern sequencing and data analysis technology.
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“Next generation sequencing,” or NGS, is the natural evolution of the work
Sanger began with his sequencing method. NGS performs sequencing in a way that is
massively parallel—i.e. collecting data on multiple similar polymerase reactions
simultaneously—and gathers millions of reads, or sequence fragments, that are then
assembled by a computer into a contiguous genome159. With the introduction of Illumina
dye sequencing in 2007, the cost to sequence a single human genome has fallen from
$1,000,000 USD in 2001 to almost $1,000 USD in 2017—a rate that surpasses Moore’s
law160.
Modern molecular biology’s dependence upon bioinformatics has increased
considerably since the conclusion of the Human Genome Project. As of 2018, the
National Center for Biotechnology Information stored the genomic information of nearly
forty thousand unique species, all publicly available for download. Modern polymerase
chain reaction (PCR) relies upon database tools such as PrimerBLAST to efficiently
design functional primers. RNA sequencing (RNA-seq) is replacing microarray
technology in differential gene expression analysis. The falling cost of genome
sequencing has made the challenge of characterizing the small nucleotide polymorphisms
(SNPs) responsible for certain devastating genetic diseases far more approachable to
research scientists. Bioinformatics is also poised to elucidate some of the more arcane
questions in biology, most of which reside in the growing field of metagenomics:
questions about the human microbiome, the ecologies of microorganisms, and the
evolution of macroorganisms.
In the year 2000, the late Stephen Hawking said, “I think the next century will be
the century of complexity.” As scientists, we should be prudent with regard to where our
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fields are heading, and we should seek the skills we will require to sustain productive
careers. Adapting to the influence of bioinformatics and the complexity it brings will
require combining knowledge of computers, statistics, and molecular biology.
A.2

Genomics

Genomics involves the sequencing and analysis of genomes. Genomes are the
complete record of potentially-expressible proteins an organism possesses, and molecular
biology has become increasingly reliant upon genome sequence information over the last
several decades. Even a technique as ubiquitous as PCR requires a genomic database to
design primers. Understanding how genomic information is obtained is important for the
molecular biologist seeking to utilize bioinformatics for its data-gathering and analytical
power. Familiarity with the sequencing process is helpful, but it is far more important to
understand how to analyze the data obtained from NGS. NGS data analysis processes are
ever changing because the tools are ever changing. The process is an art, and the rules are
established by consensus—however, the basic principles are static, and they serve as a
guide. With journals wanting increasingly complex results, NGS is quickly becoming an
indispensable tool to modern molecular biology because of the enormous amount of data
it can yield and the stories that it can tell.
A.2.1

The FASTQ File
Modern bioinformatics depends upon massively parallel sequencing—that is, a

large number of DNA sequence reads being generated simultaneously in the same run. A
sequencer records the information it collects from the flow cells during sequencing in a
digital format. This format, known as a FASTQ file, contains the sequence information of

92
every read obtained by the sequencing machine as well as quality information
representing the confidence in the accuracy of each individual base call.
FASTQ files are text files, but they rely on a specific set of formatting rules that
allow them to be used in computer applications. An example of a FASTQ file is provided
in Figure 5-1 below. The arrangement of information within a FASTQ file for each
individual read is as follows:
Line 1: Begins with @ (“at sign”) and is regarded as the first header. Information
represented here relates to the sequencer used to perform the reads, the flow cell lane, the
lane tile, and if the read is a member of a pair.
Line 2: Displays the nucleotide base calls.
Line 3: Begins with + (“plus sign”). The information from Line 1 is often
repeated here, but leaving this line blank beyond the + reduces the file size of the FASTQ
file.
Line 4: Displays the quality sequence in ASCII format.
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Figure A-1: A typical FASTQ file showing the header (line 1), base call sequence
(line 2), second header (line 3), and the quality sequence (line 4). In most FASTQ
files, the second header is represented only by “+” and left blank afterward in order to
maintain smaller file sizes. Credit: Dr. Thiruvarangan Ramaraj, National Center for
Genome Resources.
A single FASTQ file can contain several gigabytes worth of reads, or discrete
segment of genome captured by the sequencer. The length of each read depends on the
sequencing technology used to capture the reads. For example, the sequencers built by
Illumina tend to produce a high volume of short reads (hundreds of base calls per read),
whereas PacBio’s technology captures a smaller number of long reads (millions of base
calls).
Reads form the basis for the idea of “coverage” in the bioinformatics sense.
Coverage—also known as depth—is one of the most important factors in determining the
sequencing methodology ideal for the organism a bioinformatician is trying to sequence
and the budget allotted for the sequencing. Coverage can be defined mathematically, and
the formula is provided below in Eq. A-1:
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𝐶𝑜𝑣𝑒𝑟𝑎𝑔𝑒 = 𝑁 ×

𝐿
𝐺

Eq. A-1

Where N is the number of reads obtained from sequencing, L is the average length of the
reads, and G is the original genome length. For example, if a bioinformatician is
interested in sequencing a human genome which is 3.0 billion base pairs long, and a
sequencer produces 50 million reads with an average length of 500 base pairs, the
coverage for this sequencing run is 8.3x. This means that there is an 8-fold sequence
redundancy in the collected reads within the FASTQ file. While more coverage
guarantees a more complete genome assembly, an increase in coverage comes at an
increase in cost.
A.2.2

Quality Control
Genome assembly is a time-consuming and processor-heavy endeavor, so before

proceeding to assembly using the FASTQ files obtained from sequencing, the files must
first be examined for quality. Fortunately, as stated above, FASTQ files possess an
inherent quality record for every base call, so all that is required is software that can parse
that data and present it in a human-readable format.
This quality record is represented in the fourth line of the FASTQ file as a Phred
score. The system of Phred quality scoring was developed during the Human Genome
Project as a way to efficiently measure the probably of incorrect base calls in highthroughput data. The Phred score is calculated by the following equation Eq. 4-2161:
𝑞 = −10 × log10 (𝑝)

Eq. 4-2

Where q is the quality score of the base call and p is the estimated probably that the base
call is incorrect. This means that a base call with a Phred score of 40 has a 1 in 10,000
chance of being wrong161. In order save space within FASTQ files, Phred scores utilize
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the ASCII character chart to represent the quality score of each base call as a single
character. That chart is provided in Figure A-1 below162.
Table A-1: ASCII character table utilized by the Phred score system162.

FastQC is a free Java application developed by the Bioinformatics Group at the
Babraham Institute in the United Kingdom. FastQC examines high-throughput data from
a FASTQ file and compiles the quality control data into an HTML file that can be opened
by a web browser. One of the most important quality metrics, per base sequence quality,
is shown in Figure A-2 below. FastQC can also show the frequency of gaps in the read
sequences which are represented in the FASTQ by N’s. An N denotes a nucleotide for
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which a base call could not be accurately assigned by the sequencer, and excessive gaps
can be detrimental for assembly.

Figure A-2: An example of very high quality FASTQ data. The Phred scores for each
base call within each read are above 30. Each read in this FASTQ file was 101 bases
long, and there was a total of 9,454,898 reads contained within the file.
A.2.3

Genome Assembly
Jigsaw puzzles are an enjoyable group pastime that is time consuming, often

taking days or weeks to complete a single puzzle with a thousand pieces. Usually, the
unassembled puzzle pieces come inside a box that has the complete picture printed on the
cover which can be used as a reference in order to complete the assembly. Completing
the jigsaw puzzle relies on the assemblers’ abilities to recognize patterns and shapes and
interlock the pieces in the correct order.
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Replace a group of people with a cluster of parallel processors, increase the
number of pieces from a thousand to millions, and genome assembly operates essentially
the same way. Instead of a forming a picture, genome assembly takes the reads stored
within FASTQ files and assembles them into a FASTA file as a set of long, contiguous
sequences. Ideally, each contiguous sequence is a full chromosome. Fortunately, the logic
and speed of modern computers grants them advantages over human brains even for
computer processors that are not working in parallel.
This advantage manifests itself in the mathematical and computational principle
known as graph theory. Graph theory employs graphs to establish relationships between
objects. Graphs are mathematical representations composed of nodes or vertices
connected together by edges or lines. The modern approach to assembling short-read
Illumina sequences is by solving via a de Bruijn graph.
In order to understand how using a de Bruijn graph aids in genome assembly, the
concept of the k-mer must be introduced first. Suppose that an Illumina sequencer created
a FASTQ file containing reads that are each one-hundred base pairs long. This read is
referred to as a string, and its string length L is equal to 100. A k-mer is a substring—that
is, a section of the original string whose length, k, is less than L. Any k-mer length
between 2 and 𝐿 − 1 is possible. The number of possible k-mers obtained from a given kmer length k and for a given string length L is 𝐿 − 𝑘 + 1, which for 𝐿 = 100, and 𝑘 =
55, the number of k-mers per read is 46. Of course, if a k-mer length of 35 were chosen
instead, the number of k-mers per read would be 66. The important caveat to remember is
that each k-mer must overlap its adjacent k-mer in the read by 𝑘 − 1, meaning that a kmer will overlap its neighbor for every base call except once at the beginning or the end.
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When applied to the de Bruijn graph, every single k-mer substring from every
read is assigned to an edge of the graph while both connecting nodes are assigned the
prefix or suffix of that substring. The k-mer sequence AGTCAATG would be represented
by an edge in the graph, so the preceding node would be 𝑘 − 1 (AGTCAAT) and the
following node would also be 𝑘 − 1 (GTCAAT). Thus, the two nodes are bridged by the
k-mer sequence, and both the preceding and subsequent nodes overlap with edges
representing other k-mers that connect to other nodes ad infinitum until all k-mers have
been incorporated into the graph. Figure A-3 below illustrates this process, and is based
on the explanation and figures authored by Compeau et al163.

Figure A-3: An example of a de Bruijn graph being applied to the process of genome
assembly. Each edge represents a k-mer substring, and each node either the prefix of
the subsequent edge or the suffix of the preceding edge. Together, the edges of the
graphs are the individual puzzle pieces used to solve the larger assembly.

Contigs and Scaffolds
During the course of genome assembly, sequence reads are joined together into
continuous sequences known as contigs. Each contig represents a section of the genome
that has been rebuilt by a collection of overlapping reads, and for this reason, contigs are
considered consensus sequences. The assembly of larger, more complete contigs is aided
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by greater sequencing depth, because greater depth results in more sequence reads that
may potentially overlap164.
One method that overcomes the problem of sequencing depth is the paired-end
read. This sequencing technology produces two reads for each sequence fragment that are
separated from each other by a predefined genomic distance. Because each read pair is
separated by such a distance, this enables the assembly of contigs into scaffolds—that is,
a sequence composed of contigs and gaps of defined lengths which are denoted by “N.”
Paired-end reads aid the overall accuracy of assembly software by reducing the assembly
problems brought about by highly repetitive sequences or GC-rich sequences that are
more difficult to read and thus suffer from decreased depth. Contigs and scaffolds are
illustrated in Figure A-4164.

Figure A-4: Paired-end reads are assembled into contigs and scaffolds. Gaps in the
scaffold are denoted with “N.”
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A.2.4

The FASTA File
A FASTA file is produced once final assembly is complete. The FASTA is

simpler than the FASTQ format as the former contains only two lines:
Line 1: Begins with > (“greater-than”) and is header. Information represented here
establishes what the following sequence information actually represents.
Line 2: Displays the nucleotide sequence representing the assembled genome.
A FASTA file containing a fully assembled human genome would provide a
header for each chromosome followed by that chromosome’s sequence as shown in
Figure A-5.

Figure A-5: The beginning of the FASTA file for the med12 nucleotide sequence
contained in human chromosome X showing the header (line 1) and assembled
sequence (line 2). Courtesy of the National Center for Biotechnology Information.
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A.2.5

Annotation
Before an assembled genome can be published, it must first be annotated.

Annotation is the process whereby software identifies both the physical elements
(structural annotation) and biological function of those elements (functional annotation)
of an assembled genome. Structural annotation is concerned with locating and labeling
genes, coding domain sequences, exons, introns, and promoters. Identification of
genomic structures is performed either by using experimental evidence or ab initio—i.e.,
without experiment evidence. Often, experimental evidence-based approaches to
structural annotation rely on sequence homology between similar species in order to
identify genes; therefore, it is possible to annotate genes in an unannotated organism by
using a close relative that has been previously annotated. Ab initio structural annotation
relies on computer algorithms and machine learning to build probabilistic models which
in turn allow predictions about gene locations to be made. Such methods rely on Hidden
Markov Models or support-vector machines165.
Functional annotation is responsible for assigning biological roles for each
annotated structure. If an identified gene is either known or putative according to
database information, assignments include the name of a particular gene, its role in a cell,
and any motifs that the expressed protein may possess. Sometimes, functional annotation
may identify a gene that expresses a protein of an unknown function. When annotating
novel genomes, it is possible to find many genes identified structurally but that are
deemed hypothetical: a nucleotide sequence that possesses the structural hallmarks of a
gene but which has not been previously characterized165. The completeness of functional
annotation relies heavily on experimental information supplied to and cataloged in online

102
databases by research scientists. This highlights the interdependence of bioinformatics
and foundational molecular biology research. Annotation produces a general feature
format (GFF) file.
A.3

Transcriptomics

As genomics concerns itself with assembling and studying genomes, transcriptomics
concerns itself with transcriptomes. The transcriptome of an organism or a cell is the
collection of transcribed messenger RNA (mRNA) molecules that that organism or cell
possesses at any given time. That is, the transcriptome is the record of all genes currently
being expressed by an organism. Transcriptomics is of great interest to the study of gene
expression as it can reveal genome-wide changes in transcriptional control due to a
knockout or knockdown experiment, and this has presented opportunities for
advancement in many fields, particularly stem cell self-renewal and differentiation.
A.3.1

RNA Purification and RNA-seq
In order to sequence the transcriptome, RNA must be extracted from cellular

material, leaving behind DNA, proteins, and lipids. Such extraction is commonly
performed via the phenol chloroform extraction method.
Of course, mRNA transcripts are not the only type of RNA present within a cell.
Ribosomal RNAs (rRNA), which are required for mRNA translation by ribosomes but
are not part of the transcriptome, account for a significant share of total RNA—enough to
significantly overwhelm transcriptomic data with irrelevant sequences if allowed to be
included in sequencing. Many commercially-available kits exist that deplete rRNA.
Because rRNA sequences are identical, most of these kits function by hybridizing rRNA
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to complimentary oligonucleotides and remove it either through precipitation or RNase
degradation.
After purification, the mRNA is fragmented and then reverse-transcribed into
complimentary DNA (cDNA) followed by PCR amplification. This amplified cDNA is
then sequenced and FASTQ files are generated as output that can then be analyzed166.
A.3.2

RNA-seq Read Mapping
There are three main strategies for analyzing RNA-seq data, and each relies on the

availability of reference genomes or transcriptomes. The first method involves mapping
RNA-seq reads to a reference genome, eliminating the need to assemble those reads into
transcripts. Because of the presence of alternative splicing and the absence of introns,
mapping directly to a genome is a computationally-intensive process. This method can be
easily employed to study human mRNA samples due to the existence of assembled and
annotated human genomes; however, if no genome annotation file exists, this method
allows for the functional annotation of novel transcripts166,167.
The second method involves mapping to a pre-existing annotated transcriptome.
The advantage with this method is speed and a lower computational requirement since
introns are no longer a factor. The disadvantage of this method is that it offers no way to
discover novel genomes, unlike when mapping to a genome166,167.
The third method requires the assembly of a transcriptome when no reference
genome or transcriptome exists. Like in genome assembly, the RNA-seq reads are
assembled into contigs and transcripts, and then the reads are mapped back to those
transcripts, counted, and then functionally annotated166,167.
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A.3.3

Differential Gene Expression Analysis
Of course, like with genome assembly, the quality of RNA-seq data depends on

sequencing depth, and greater depth comes at a cost. Also, in order for the obtained data
to be statistically relevant, at least three replicates are required.
The chief hurdle that must be overcome with the analysis of RNA-seq data is the
problem of normalization. Not all genes are the same size, and not all genes are equally
expressed. What this means is that genes that are either very large or very highly
expressed will have disproportionately large numbers of reads that map to their
transcripts. RNA-seq normalization employs a metric to differentiate high read counts as
being due to high gene expression rather than large gene size, and this metric is known as
RPKM: Reads Per Kilobase per Million mapped reads. The equation for RPKM is below
(Eq. 4-3).
𝑅𝑃𝐾𝑀 = 𝐶 /(𝑁 × 𝐿)

Eq. 4-3

Where C is the number of reads mapping to a feature (transcript, exon, etc.), N is the
length of the feature in kilobases, and L is the total number of mappable reads in millions.
This concept is illustrated in Figure A-6.
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Figure A-6: RPKM accounts for gene size, reads mapped to a gene, and total number
of mappable reads in order to normalize RNA-seq data.
Quality control for RNA-seq data involves using dimensionality reduction
techniques to plot patterns of clustering. The techniques used include multidimensional
scaling, principal component analysis, and histograms with dendrograms. Most of the
statistical theory involving these quality control techniques is beyond the scope of this
brief overview of bioinformatics disciplines, but more information about the
bioinformatics application of principal component analysis can be found in a review by
Shuangge Ma and Ying Dai168.
Once the quality of the data has been determined, quantitative analysis can begin.
Two of the most well-known programs for performing differential gene expression
analysis are edgeR and DESeq2. What these programs do first is determine the normal
variability in gene expression. Then, they compare the data points of the expression of the
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experimental groups to determine their similarity in distribution. Finally, the distribution
results are statistically analyzed to determine the p-values of the data to establish
significance. For a more detailed explanation about how DESeq works in differential
gene expression analysis, refer to the paper by Simon Anders and Wolfgang Huber169.
A.4

Metagenomics

Metagenomics is a new and growing field of research and bioinformatic
techniques involving the study of communities of organisms and their gene compositions
as a whole. The primary significance of the emergence is that for many decades, the
study of prokaryotic organisms as taken place in isolated cultures and controlled
environments. Now, through metagenomics, entire communities of microorganisms can
be collected from soil samples, gastrointestinal tracts, or other places and their genetic
information can be sequenced, revealing information about those communities such as
the genes that exist in that community, the different populations present in that
community, and how environment can play a role in the composition of the community.
Metagenomics is the bioinformatic method by which microbiomes can be better explored,
and it has the potential to help humans be better stewards of their own microbiomes,
hopefully leading to a revolution in how broad-spectrum antibiotics are used and how
certain environmental issues can be overcome. For more information on metagenomics,
refer to the publication The New Science of Metagenomics by the National Research
Council (US) Committee on Metagenomics170.
A.5

Internship

The Summer 2018 internship took place at the National Center for Genome
Resources (NCGR) located in Santa Fe, New Mexico. NCGR grew out of the Human
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Genome Project as an offshoot of the Los Alamos National Laboratory less than 40 miles
away. Currently, NCGR operates as a non-profit research institute that focuses on the
analysis of NGS data rather than on sequencing itself, and this is due to the Moore’s
Law-style speed at which sequencing technology is improving.
NCGR operates its own data center, and participants were allowed to see the
servers in operation within their server room. All work performed for the internship took
place on a small set of server blades that was named “Logrus,” inspired by the maze set
in the Chronicles of Amber fiction written by Roger Zelazny who was a resident of Santa
Fe for a number of years. Logrus ran a Linux distribution that was accessible via terminal
emulators like PuTTY on laptops.
Before the internship began, participants were required to take an online course
on Linux to learn how to use the operating system and interact with the Linux shell using
the Bourne Again Shell (Bash) command language. This was primarily meant to gauge a
willingness to learn. Once the internship began, Bash was reintroduced, and participants
were taught how to interface with the Logrus server. Figure A-7 shows the introduction
to the command line interface in the Linux terminal.
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Figure A-7: The command line interface on the 64-bit PuTTY terminal emulator.
Shown is the user “jstraub” on the Logrus server and the process of basic
familiarization with Bash commands and Linux file directories.
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The average day at NCGR consisted of morning lectures and afternoon
workshops, broken by a 90-minute break for lunch. The first two weeks of the six-week
program involved genomics. Interns were instructed on the basics of NGS technology
and approaches to sequencing, particularly those of Illumina and Pacific Biosciences.
They were then taught the methods by which genomes are sequenced and assembled,
including workflows. These workflows were then applied using terminal emulators to the
Logrus server.
The first real assignment after the necessary familiarization with the Linux
environment, Bash, and the working directories was to assemble the genomes of five
different strains of Staphylococcus aureus: MM66, MM66-4, MM61, MM25, and MV8.
This was done as part of a two-week workshop on genome assembly. The sequence
information supplied was in the form of Illumina GAII paired-end reads. The software
used included SOAPdenovo and SPAdes, and the work was performed in a detached
screen so that other work could be performed. A screenshot of SPAdes assembling the S.
aureus MV8 genome is shown in Figure A-8 and Figure A-9.
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Figure A-8: Active assembly of the S. aureus MV8 genome using the SPAdes
software. Shown predominately is the process of splitting the FASTQ files into kmers.
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Figure A-9: Active assembly of the S. aureus MV8 genome using the SPAdes
software continued. This screenshot was taken during a mapping step.
The FASTA file generated by SPAdes (named “scaffolds.fasta”) contained the
assembled genome of S. aureus MV8. Of course, as revealed in Figure A-10 below, the
genome was not entirely complete. The FASTA file contained 370 separate scaffolds
which SPAdes could not accurately piece together, and this is due to the nature of
shotgun sequencing—a problem that can be solved at the cost of increased sequencing
depth. N50 is perhaps the most important metric taken into consideration which assessing
overall completeness of any given assembly. N50 is defined as the largest length L such
that 50% of all nucleotides are contained in contigs of sizes that are at least L.
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Figure A-10: Analysis of the S. aureus MV8 FASTA file. The FASTA was
composed of 370 scaffolds ranging from 80 to 297,298 nucleotides and totaling
3,125,157 nucleotides. Less than 35% of the assembled scaffolds were of a size
greater than 1,000 nucleotides, but of those scaffolds, only 0.22% of the nucleotides
were gaps. 90.5% of scaffolds contained only a single contig, and the number of
contigs numbered 457. The N50 contig length was 143,607 nucleotides, meaning that
50% of nucleotides were contained in contigs larger than that length.
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After conducting the assembly of Illumina reads, interns were instructed to
assemble longer PacBio reads of Janthinobacterium using CANU. A screenshot of that
process is shown in figure.

Figure A-11: Assembly of Janthinobacterium PacBio reads. Most read lengths are
between 1,000 and 1,999 nucleotides.
HMMER was used to align the assembled prokaryotic genomes to the Pfam
database. A screenshot of HMMER being used by the interns as seen in the Linux “top”
program is shown in Figure A-12. Top is the main Linux program responsible for
showing system usage statistics. RAST was then used to annotate the genomes both
structurally and functionally and produce a GFF file (Figure A-13).
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Figure A-12: The “top” command running in the main screen of the PuTTY terminal.
Most user jobs consisted of running the “hammer” program in detached screens.
%CPU usage of 200.0 equates to using the equivalent of two CPUs on a process. The
information displayed by top is updated every 3 seconds by default.
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Figure A-13: RAST performing annotation for the aligned genome to produce a GFF
file.
Created files that required use beyond the Linux environment could be placed into
a directory named “www.” This directory could be accessed using a web browser such as
Google Chrome (Figure A-14).
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Figure A-14: A subfolder of the www folder contained within user jstraub’s home
directory.
The next week consisted of a workshop on variant calling which entailed the
identification of genuine small nucleotide polymorphisms (SNPs) and differentiating
those from sequencing errors. The Freebayes software was used to compare human
samples against a human reference genome. The significance of this exercise was in
showing the process for determining the allelic makeup of a sampled individual which
has use in determining carrier status for genetic diseases such as Tay Sachs.
The workshop on RNA-seq and differential gene expression immediately
followed variant calling. First, human RNA-seq data was aligned to a human reference
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genome using STAR. Then, FeatureCount was used to generate a count of all RNA-seq
reads. Finally, differential gene expression analysis was performed using DESEQ2.
Figure A-15 shows a principal component analysis of the RNA-seq data for quality
control purposes.

Figure A-15: Principal component analysis of RNA-seq data. The four different
datasets are clustering together which indicates good quality data.
The figure above was created using R. An entire workshop involving visualizing
data using R was included in the internship. In the effort of keeping this chapter brief, the
principal component analysis will serve as the only example of that work. Finally, a short
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workshop on metagenomics concluded the internship, and this was coupled with a helpful
lecture on the virtues of being a good software user in the relatively new field of
bioinformatics.
This internship not only allowed for a six-week stay in the beautiful state of New
Mexico, but it revealed a new side of biology that is interested in big data problems—
problems that can only be solved by large computers, efficient software, and creative
imaginations. Six weeks was not enough to gain any proficiency in the myriad techniques
presented during the program except for Linux command line operation; however, the
hands-on familiarity with the techniques presented was more than enough to justify the
time spent participating in the program. That familiarity helped to cement a foundation
upon which further bioinformatics training could be built.
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APPENDIX B
TABLE OF PRIMERS

Table B-2: Primers used in qRT-PCR.
Gene
Med31
Med12
Med13
Cdk8
Ccnc
Pparg
Lpl
Srebp-1c
Adiponectin
Gapdh
Tuba1a

Sequence (5`→3`)
F: GTTTGTTATGGCCGCTGCTG
R: CCTCTTTGGGCAAGAAAATTAAGGT
F: CGAAAAGGGACAGCAGAAAC
R: CCCATCCTCCCCACCTAAGA
F: TGTCCTGCTCCTTCACCTTTT
R: GGCATAAGATAACTTGAAATGGGCT
F: GCCAAGAGGAAAGATGGGAAGG
R: GCCGACATAGAGATCCCAGTT
F: GCTGATTTGATCGAGGAGCG
R: ATCCATTGCAAATAGTGGGAGC
F: GTGGTACTTTACGCCTCGGT
R: GCTCGGTTACTCCCCGTTTC
F: CCGCCGACCAAAGAAGAGAT
R: TAGCCACGGACTCTGCTACT
F: CTCTTGAAGCCTTCCTGAG
R: GCACTGACTCTTCCTTGAT
F: TTCCATACCAGAGGGGCTCA
R: GAGTCGTGGTTTCCTGGTCA
F: ACTAGGCGCTCACTGTTCTCT
R: CAATACGACCAAATCCGTTGACT
F: CCAGGGCTTCTTGGTTTTCC
R: CGCTCAATGTCGAGGTTTCT
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Product
Length (bp)
129
87
150
77
148
70
117
138
89
99
?
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